UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)	QUARTERLY REPORT PURSUANT TO SECTION For the q	N 13 OR 15(d) OF THE SECU warterly period ended June 30, OR		
	TRANSITION REPORT PURSUANT TO SECTION	` '	RITIES EXCHANGE	
	ACT OF 1934 FOR THE TRANSITION PERIOD	FROMTO		
	Col	mmission file number: 1-10989		
		Ventas, Inc.		
	(Exact Name	e of Registrant as Specified in Its	Charter)	
	Delaware (State or Other Jurisdiction of Incorporat	ion or Organization)	61-1055020 (I.R.S. Employer Identification No.)	
	38	53 N. Clark Street, Suite 3300 Chicago, Illinois 60654 ss of Principal Executive Offices		
	(Registrant's	(877) 483-6827 Telephone Number, Including Ar	rea Code)	
	Securities regis	tered pursuant to Section 12(b)	of the Act:	
	Title of Each Class	Trading Symbol	Name of Exchange on Which Regist	tered
	Common Stock \$0.25 par value	VTR	New York Stock Exchange	
	eate by check mark whether the registrant (1) has filed all renonths (or for such shorter period that the registrant was req \square No \square		` '	ring the
	eate by check mark whether the registrant has submitted elec- nis chapter) during the preceding 12 months (or for such sho	• •	•	gulation S-T
	cate by check mark whether the registrant is a large accelera ny. See the definitions of "large accelerated filer," "accelera			
Large acceler Smaller repor		Accelerated filer □	Non-accelerated filer Emerging growth company	
	emerging growth company, indicate by check mark if the runting standards provided pursuant to Section 13(a) of the E	-	e extended transition period for complying with any new o	or revised
Indi	cate by check mark whether the registrant is a shell company	y (as defined in Rule 12b-2 of the	Exchange Act). Yes \square No \boxtimes	
As o	f July 30, 2024, there were 413,153,787 shares of the registr	rant's common stock outstanding.		

VENTAS, INC. FORM 10-Q

INDEX

		Page
PART I—F	FINANCIAL INFORMATION	
Item 1.	Consolidated Financial Statements (Unaudited)	1
	Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023	1
	Consolidated Statements of Income for the Three and Six Months Ended June 30, 2024 and 2023	2
	Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2024 and 2023	3
	Consolidated Statements of Equity for the Three and Six Months Ended June 30, 2024 and 2023	4
	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023	6
	Notes to Consolidated Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	31
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	58
Item 4.	Controls and Procedures	60
PART II—	OTHER INFORMATION	
Item 1.	Legal Proceedings	61
Item 1A.	Risk Factors	61
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	61
Item 3.	Defaults Upon Senior Securities	61
Item 4.	Mine Safety Disclosures	61
Item 5.	Other Information	61
Item 6.	Exhibits	62

PART I—FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

VENTAS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts, unaudited)

	As	of June 30, 2024	As of	December 31, 2023
Assets				
Real estate investments:				
Land and improvements	\$	2,588,599	\$	2,596,274
Buildings and improvements		27,358,282		27,201,381
Construction in progress		410,663		368,143
Acquired lease intangibles		1,454,473		1,448,146
Operating lease assets		312,812		312,142
		32,124,829		31,926,086
Accumulated depreciation and amortization		(10,647,898)		(10,177,136)
Net real estate property	·	21,476,931		21,748,950
Secured loans receivable and investments, net		36,195		27,986
Investments in unconsolidated real estate entities		608,844		598,206
Net real estate investments	_	22,121,970		22,375,142
Cash and cash equivalents		557,082		508,794
Escrow deposits and restricted cash		58,202		54,668
Goodwill		1,045,071		1,045,176
Assets held for sale		43,261		56,489
Deferred income tax assets, net		1,657		1,754
Other assets		702,986		683,410
Total assets	\$	24,530,229	\$	24,725,433
Liabilities and equity				
Liabilities:				
Senior notes payable and other debt	\$	13,175,077	\$	13,490,896
Accrued interest		122,132		117,403
Operating lease liabilities		213,110		194,734
Accounts payable and other liabilities		1,003,078		1,041,616
Liabilities related to assets held for sale		4,988		9,243
Deferred income tax liabilities		32,660		24,500
Total liabilities		14,551,045		14,878,392
Redeemable OP unitholder and noncontrolling interests		311,468		302,636
Commitments and contingencies				
Equity:				
Ventas stockholders' equity:				
Preferred stock, \$1.00 par value; 10,000 shares authorized, unissued				
Common stock, \$0.25 par value; 600,000 shares authorized, 413,154 and 402,380 shares outstanding at June 30, 2024 and December 31, 2023, respectively		103,242		100,648
Capital in excess of par value		16,135,972		15,650,734
Accumulated other comprehensive loss		(17,409)		(35,757)
Retained earnings (deficit)		(6,577,395)		(6,213,803)
Treasury stock, 2 and 279 shares issued at June 30, 2024 and December 31, 2023, respectively		(25,060)		(13,764)
Total Ventas stockholders' equity		9,619,350		9,488,058
Noncontrolling interests		48,366		56,347
Total equity		9,667,716		9,544,405
Total liabilities and equity	\$	24,530,229	\$	24,725,433
1 2				

VENTAS, INC. CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share amounts, unaudited)

Outpatient medical and research portfolio 218,853 215,807 437,730 418,81 Resident fees and services 817,600 372,787 370,162 747,032 722,900 Third party capital management revenues 4,332 3,996 8,628 8,171 Income from loons and investments 1,200,980 1,106,38 2,400,804 2,183,600 Total creames 1,200,980 1,106,38 2,400,804 2,183,600 Expense 1 149,259 143,265 2,901,22 271,340 Depreciation and amortization 339,884 304,689 640,103 586,800 Property-level operating expenses: 803,559 547,110 1,213,180 1,843,250 Property-level operating expenses: 803,559 547,110 1,213,180 1,843,33 Outpatient medical and research portfolio 73,286 572,171 1,412,24 1,339,88 Triple-net leased 35,00 3,537 7,244 7,33 6,614 7,244 7,33 General, administrative and profesional fees 37,727 <td< th=""><th></th><th>For</th><th colspan="3">For the Three Months Ended June 30,</th><th>1</th><th>For the Six Mont</th><th>hs Er</th><th colspan="3">Ended June 30,</th></td<>		For	For the Three Months Ended June 30,			1	For the Six Mont	hs Er	Ended June 30,		
Renta Carrier Carrie			2024		2023		2024		2023		
Triple-net leased	Revenues										
Outpatient medical and research portfolio 218,853 215,807 437,730 418,81 Resident fees and services 817,600 372,787 370,162 747,032 722,900 Third party capital management revenues 4,332 3,996 8,628 8,171 Income from loons and investments 1,200,980 1,106,38 2,400,804 2,183,600 Total creames 1,200,980 1,106,38 2,400,804 2,183,600 Expense 1 149,259 143,265 2,901,22 271,340 Depreciation and amortization 339,884 304,689 640,103 586,800 Property-level operating expenses: 803,559 547,110 1,213,180 1,843,250 Property-level operating expenses: 803,559 547,110 1,213,180 1,843,33 Outpatient medical and research portfolio 73,286 572,171 1,412,24 1,339,88 Triple-net leased 35,00 3,537 7,244 7,33 6,614 7,244 7,33 General, administrative and profesional fees 37,727 <td< td=""><td>Rental income:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Rental income:										
Resident fees and services 372,787 370,162 747,032 722,902 Resident fees and services 817,600 724,614 1,50,004 1,229,60 Income from loans and investments 1,436 6,534 2,725 20,14 Incerest and other income 1,200,980 1,106,38 2,400,894 2,183,60 Expense 1,200,980 1,106,38 2,400,894 2,218,300 Expense 1,200,980 1,146,65 2,99,192 2,213,400 Interest 1,420,59 1,426,50 2,99,192 2,213,400 Interest and ond amortization 339,848 304,689 60,013 5,868 Property-level operating expenses 603,359 547,110 1,213,180 1,843,33 Outper operating expenses 1,650 1,343 3,403 3,144	Triple-net leased	\$	153,934	\$	154,355	\$	309,302	\$	304,094		
Resident fees and services 817,600 724,614 1,630,904 8,628 8,171 Inicip antry capital management revenues 4,332 3,96 8,628 8,171 Incene from loans and investments 1,436 6,554 2,725 20,14 Interest and other income 1,200,908 1,106,38 2,008,90 2,713,40 Total revenues 1,200,908 1,436,58 2,901,20 2,713,40 Depreciation and amortization 339,84 30,468 2,901,20 2,713,40 Depreciation and amortization 603,359 547,110 1,213,180 1,884,33 Outpatient medical and research portfolio 73,266 3,577 7,244 7,33 Outpatient medical and research portfolio 73,266 3,577 7,244 7,33 Tiple ent leased 1,560 1,435 3,604 3,504 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604 3,604	Outpatient medical and research portfolio		218,853		215,807		437,730		418,811		
Third party capital management revenues			372,787	'	370,162		747,032		722,905		
Income from loans and investments	Resident fees and services		817,600		724,614		1,630,904		1,429,607		
Interest and other income	Third party capital management revenues		4,332		3,996		8,628		8,173		
Total revenues	Income from loans and investments		1,436		6,554		2,725		20,143		
Interest 149,259 143,265 299,192 271,344 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271,245 271	Interest and other income		4,825		1,032		11,605		2,775		
Interest 149,259	Total revenues		1,200,980		1,106,358		2,400,894		2,183,603		
Depreciation and amortization 339,848 304,689 640,103 586,808 Property-level operating expenses: Senior housing 603,359 547,110 1,213,180 1,084,332 Outpatient medical and research portfolio 73,286 72,171 147,224 139,084 Triple-net leased 3,506 3,537 7,244 7,333 Third party capital management expenses 1,650 1,436 3,403 3,144 General, administrative and professional fees 37,727 34,399 86,464 79,197 Loss (gain) on extinguishment of debt, net 420 (12,065) (110) (20,125 Gain on foreclosure of real estate 7,506 1,043 (12,065) (110) (20,125 Gain on foreclosure of real estate 7,507 (12,064) (12,065) (110) (20,125 Gain on foreclosure of real estate 7,507 (12,064) (12,065) (110) (20,125 Gain on foreclosure of real estate 7,507 (12,064) (13,074) (13,074) Total expenses (income) 8,128 (17,959) 6,794 (10,197 Total expenses (income) 8,128 (17,959) 6,794 (10,197 Gain on real estate dispositions, income taxes and noncontrolling interests 1,060 (1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Gain on real estate dispositions 1,060 1,043,724 2,427,480 2,109,437 Ret income from continuing operations 2,106 1,043,724 2,427,480 2,109,437 Ret income attributable to noncontrolling interests 1,761 1,600 1,040 1,	Expenses										
Property-level operating expenses: Senior housing	Interest		149,259		143,265		299,192		271,340		
Senior housing 603,359 547,110 1,213,180 1,084,337 Outpatient medical and research portfolio 73,286 72,171 147,224 139,08 Triple-net leased 3,506 3,537 7,244 7,333 Third party capital management expenses 1,660 1,436 3,403 3,147 General, administrative and professional fees 37,727 34,399 86,464 79,197 Loss (gain) on extinguishment of debt, net 420 (6,801) 672 (6,801) Gain on foreclosure of real estate 2,886 3,069 7,563 4,455 Allowance on loans receivable and investments, net (42) (12,065) (110) (20,127) Gain on foreclosure of real estate	Depreciation and amortization		339,848		304,689		640,103		586,808		
Outpatient medical and research portfolio 73,286 72,171 147,224 139,086 Triple-net leased 3,506 3,537 7,244 7,33 Third party capital management expenses 1,650 1,436 3,403 3,143 General, administrative and professional fees 37,727 34,399 86,464 79,197 Loss (gain) on extinguishment of debt, net 420 (6,801) 672 (6,801) Transaction, transition and restructuring costs 2,886 3,069 7,653 4,455 Allowance on loans receivable and investments, net (42) (12,065) (110) (20,125 Gain on forcelosure of real estate — (29,127) — (29,127) Chareholder relations matters 37 — 15,751 — Other expense (income) 8,128 (17,959) 6,794 (10,195 Other expense (income) 1,220,064 1,043,724 2,427,480 2,109,43 (Loss) income before unconsolidated entities, real estate dispositions, income attributal dispositions (1,652) 31,254 (10,035)	Property-level operating expenses:										
Triple-net leased 3,506 3,537 7,244 7,33 Indicipant capital management expenses 1,650 1,436 3,403 3,414 General, administrative and professional fees 1,650 1,436 3,403 3,445 General, administrative and professional fees 3,7727 34,399 86,464 79,197 Loss (gain) on extinguishment of debt, net 420 (6,801) 672 (6,801) Transaction, transition and restructuring costs 2,886 3,069 7,563 4,455 Allowance on loans receivable and investments, net (2) (12,065) (110) (20,122) Gain on forcelosure of real estate 3 - 15,751 - - Shareholder relations matters 3 - 15,751 - - Other expense (income) 8,128 (17,959) 6,794 (10,197 Closs) income before unconsolidated entities, real estate dispositions, income tax (19,084) 62,634 26,586 74,166 Closs) income from unconsolidated entities 1,082 1,145 1,160	Senior housing		603,359		547,110		1,213,180		1,084,332		
Third party capital management expenses	Outpatient medical and research portfolio		73,286		72,171		147,224		139,084		
Third party capital management expenses	Triple-net leased		3,506		3,537		7,244		7,333		
General, administrative and professional fees 37,727 34,399 86,464 79,197 Loss (gain) on extinguishment of debt, net 420 (6,801) 672 (6,801) Transaction, transition and restructuring costs 2,886 3,069 7,563 4,455 Allowance on loans receivable and investments, net (42) (12,065) (110) (20,125) Gain on foreclosure of real estate 37 - 15,751 - Other expense (income) 8,128 (17,959) 6,794 (10,197) Total expenses 1,220,064 1,043,724 2,427,480 2,109,437 (Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests (19,084) 62,634 (26,586) 74,160 (Loss) income from unconsolidated entities (19,084) 62,634 (26,586) 74,160 (Loss) income from unconsolidated entities (19,084) 62,634 (26,586) 74,160 (Loss) income from unconsolidated entities (19,084) 62,634 (26,586) 74,160 (Loss) income from unconsolidated entities <t< td=""><td></td><td></td><td>680,151</td><td></td><td>622,818</td><td></td><td>1,367,648</td><td></td><td>1,230,749</td></t<>			680,151		622,818		1,367,648		1,230,749		
Loss (gain) on extinguishment of debt, net 420 6,801 6,72 6,801 Transaction, transition and restructuring costs 2,886 3,069 7,563 4,455 Allowance on loans receivable and investments, net 6,201 6,201 6,201 6,201 Cain on foreclosure of real estate - (29,127 - (29,127 - (29,127 6,201 6,201 6,201 6,201 6,201 Cain on foreclosure of real estate 37 - (15,751 - (29,127 6,201 6,201 6,201 6,201 6,201 6,201 6,201 Cother expense (income) 8,128 (17,959 6,794 (10,197 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201 6,201	Third party capital management expenses		1,650		1,436		3,403		3,142		
Transaction, transition and restructuring costs 2,886 3,069 7,563 4,455 Allowance on loans receivable and investments, net (42) (12,065) (110) (20,125) Gain on foreclosure of real estate — (29,127) — (29,127) Shareholder relations matters 37 — 15,751 — Other expense (income) 8,128 (17,959) 6,794 (10,197) Total expenses 1,220,064 1,043,724 2,427,480 2,109,437 (Loss) income before unconsolidated entities, real estate dispositions, income taxs (19,084) 62,634 (26,586) 74,166 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,633 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,633 (Loss) income form unconsolidated entities (1,652) 31,254 (10,035) 25,633 (Loss) income form unconsolidated entities (1,652) 31,254 (10,035) 25,635 Income from continuing operations 21,168 105,066 8,628<	General, administrative and professional fees		37,727		34,399		86,464		79,197		
Allowance on loans receivable and investments, net (42) (12,065) (110) (20,125) Gain on foreclosure of real estate - (29,127) - (29,127) Shareholder relations matters 37	Loss (gain) on extinguishment of debt, net		420		(6,801)		672		(6,801)		
Gain on foreclosure of real estate — (29,127) — (29,127) Shareholder relations matters 37 — 15,751 — Other expense (income) 8,128 (17,959) 6,794 (10,197) Total expenses 1,220,064 1,043,724 2,427,480 2,109,43 (Loss) income before unconsolidated entities, real estate dispositions, income taxs and noncontrolling interests (19,084) 62,634 (26,586) 74,166 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,63 Gain on real estate dispositions 49,670 1,405 50,011 11,600 Income tax (expense) benefit (7,766) 9,773 (4,762) 12,575 Income from continuing operations 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,000 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,976 Earnings per common stare Income from continuing operations	Transaction, transition and restructuring costs		2,886		3,069		7,563		4,455		
Shareholder relations matters 37 — 15,751 — Other expense (income) 8,128 (17,959) 6,794 (10,197) Total expenses 1,220,064 1,043,724 2,427,480 2,109,437 (Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests (19,084) 62,634 (26,586) 74,166 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,63 Gain on real estate dispositions 49,670 1,405 50,011 11,600 Income tax (expense) benefit (7,766) 9,773 (4,762) 12,577 Income from continuing operations 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,000 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,970 Earmings per common share Basic: Income from continuing operations \$ 0.05 0.26 0.01 0.3	Allowance on loans receivable and investments, net		(42)		(12,065)		(110)		(20,129)		
Other expense (income) 8,128 (17,959) 6,794 (10,197) Total expenses 1,220,064 1,043,724 2,427,480 2,109,437 (Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests (19,084) 62,634 (26,586) 74,164 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,63 Gain on real estate dispositions 49,670 1,405 50,011 11,600 Income tax (expense) benefit (7,766) 9,773 (4,762) 12,577 Income from continuing operations 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,000 Net income attributable to common stockholders 19,387 103,453 5,075 120,976 Earnings per common share 1,781 1,613 3,553 3,000 Net income attributable to common stockholders 9,05 0,26 0,01 0,33 Net income attributable to common stockholders 0,05 0,26	Gain on foreclosure of real estate		_		(29,127)		_		(29,127)		
Total expenses	Shareholder relations matters		37		_		15,751		_		
(Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests (19,084) 62,634 (26,586) 74,160 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,63 Gain on real estate dispositions 49,670 1,405 50,011 11,600 Income tax (expense) benefit (7,766) 9,773 (4,762) 12,575 Income from continuing operations 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,008 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,976 Earnings per common share Basic: Income from continuing operations \$ 0.05 0.26 0.01 0.30 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Income from continuing operations \$ 0.05	Other expense (income)		8,128		(17,959)		6,794		(10,197)		
and noncontrolling interests (19,084) 62,634 (26,586) 74,160 (Loss) income from unconsolidated entities (1,652) 31,254 (10,035) 25,63 Gain on real estate dispositions 49,670 1,405 50,011 11,600 Income tax (expense) benefit (7,766) 9,773 (4,762) 12,572 Income from continuing operations 21,168 105,066 8,628 123,978 Net income 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,000 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,976 Earnings per common share 8 8 0.05 0.26 0.01 0.36 Net income attributable to common stockholders 0.05 0.26 0.01 0.36 Diluted: Income from continuing operations \$ 0.05 0.26 0.01 0.36 Income from continuing operations \$ 0.05 0.26 0.01 0.36	Total expenses		1,220,064		1,043,724		2,427,480		2,109,437		
Gain on real estate dispositions 49,670 1,405 50,011 11,600 Income tax (expense) benefit (7,766) 9,773 (4,762) 12,575 Income from continuing operations 21,168 105,066 8,628 123,978 Net income 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,008 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,976 Earnings per common share Basic: Income from continuing operations \$ 0.05 0.26 0.01 0.36 Net income attributable to common stockholders 0.05 0.26 0.01 0.36 Diluted:¹ Income from continuing operations \$ 0.05 0.26 0.02 0.33	(Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests		(19,084)		62,634		(26,586)		74,166		
Income tax (expense) benefit	(Loss) income from unconsolidated entities		(1,652)		31,254		(10,035)		25,631		
Income from continuing operations 21,168 105,066 8,628 123,978	Gain on real estate dispositions		49,670		1,405		50,011		11,606		
Net income 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,008 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,976 Earnings per common share Basic: Income from continuing operations \$ 0.05 0.26 0.02 \$ 0.31 Net income attributable to common stockholders 0.05 0.26 0.01 0.36 Diluted:1 Income from continuing operations \$ 0.05 0.26 0.02 \$ 0.31 Income from continuing operations \$ 0.05 0.26 0.02 \$ 0.31	Income tax (expense) benefit		(7,766)		9,773		(4,762)		12,575		
Net income 21,168 105,066 8,628 123,978 Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,008 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,970 Earnings per common share Basic: Income from continuing operations \$ 0.05 0.26 0.02 \$ 0.31 Net income attributable to common stockholders 0.05 0.26 0.01 0.36 Diluted:1 Income from continuing operations \$ 0.05 0.26 0.02 \$ 0.3	Income from continuing operations		21,168		105,066		8,628		123,978		
Net income attributable to noncontrolling interests 1,781 1,613 3,553 3,008 Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,970 Earnings per common share Basic: Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Diluted:1 Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3	· ·		21,168		105,066		8,628		123,978		
Net income attributable to common stockholders \$ 19,387 \$ 103,453 \$ 5,075 \$ 120,970 Earnings per common share Basic: Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Diluted:1 Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3	Net income attributable to noncontrolling interests								3,008		
Earnings per common share Basic: Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.31	and the second s	\$		\$		\$		\$	120,970		
Basic: Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Diluted:1 Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3		=				=		Ė			
Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3 Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Diluted:1 Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.3											
Net income attributable to common stockholders 0.05 0.26 0.01 0.30 Diluted: 1 Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.31		\$	0.05	\$	0.26	\$	0.02	\$	0.31		
Diluted: 1 Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.31		Ψ		Ψ		φ		φ	0.31		
Income from continuing operations \$ 0.05 \$ 0.26 \$ 0.02 \$ 0.31			0.03		0.20		0.01		0.50		
		\$	0.05	\$	0.26	\$	0.02	\$	0.31		
Net income autinuanie to common stockholders 1115 1176 1111 1130	Net income attributable to common stockholders	Ψ	0.05	Ψ	0.26	Ψ	0.02	Ψ	0.31		

¹ Potential common shares are not included in the computation of diluted earnings per share ("EPS") when a loss from continuing operations exists as the effect would be an antidilutive per share amount.

VENTAS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In thousands, unaudited)

	For the Three Months Ended June 30,				For	the Six Mont	hs En	ded June 30,
	2024 2023				2024		2023	
Net income	\$	21,168	\$	105,066	\$	8,628	\$	123,978
Other comprehensive income:								
Foreign currency translation gain		3,189		1,881		7,124		5,780
Unrealized loss on available for sale securities		(842)		_		(722)		_
Unrealized (loss) gain on derivative instruments		(1,570)		28,001		9,452		19,199
Total other comprehensive income		777		29,882		15,854		24,979
Comprehensive income		21,945		134,948		24,482		148,957
Comprehensive income attributable to noncontrolling interests		413		5,578		1,059		5,739
Comprehensive income attributable to common stockholders	\$	21,532	\$	129,370	\$	23,423	\$	143,218

VENTAS, INC. CONSOLIDATED STATEMENTS OF EQUITY

For the Three Months Ended June 30, 2024 and 2023 (In thousands, except per share amounts, unaudited)

For the Three Months Ended June 30, 2024

	Common tock Par Value	Capital in Excess of Par Value	Accumulated Other Comprehensive (Loss) Income	Retained Earnings (Deficit)	-	Freasury Stock	;	Total Ventas Stockholders' Equity	Noncontrolling Interests	Т	otal Equity
Balance at April 1, 2024	\$ 101,094	\$ 15,756,414	\$ (19,554)	\$ (6,410,144)	\$	(24,970)	\$	9,402,840	\$ 55,993	\$	9,458,833
Net income	_	_	_	19,387		_		19,387	1,781		21,168
Other comprehensive income (loss)	_	_	2,145	_		_		2,145	(1,368)		777
Net change in noncontrolling interests	_	(12,216)	_	_		_		(12,216)	(8,040)		(20,256)
Dividends to common stockholders—\$0.45 per share	_	22	_	(186,638)		_		(186,616)	_		(186,616)
Issuance of common stock for stock plans, restricted stock grants and other	2,148	418,019	_	_		(90)		420,077	_		420,077
Adjust redeemable OP unitholder interests to current fair value	_	(25,467)	_	_		_		(25,467)	_		(25,467)
Redemption of OP Units		(800)						(800)			(800)
Balance at June 30, 2024	\$ 103,242	\$ 16,135,972	\$ (17,409)	\$ (6,577,395)	\$	(25,060)	\$	9,619,350	\$ 48,366	\$	9,667,716

For the Three Months Ended June 30, 2023

	Common Stock Par Value		Stock Par Value Excess of Par Value		Accumulated Other Comprehensive (Loss) Income		Retained Earnings (Deficit)		Treasury Stock		Total Ventas Stockholders' Equity		Noncontrolling Interests		otal Equity
Balance at April 1, 2023	\$	100,065	\$	15,562,017	\$	(40,469)	\$ (5,611,067)	\$	(13,555)	\$	9,996,991	\$	67,611	\$	10,064,602
Net income		_		_		_	103,453		_		103,453		1,613		105,066
Other comprehensive income		_		_		25,917	_		_		25,917		3,965		29,882
Net change in noncontrolling interests		_		3,463		_	_		_		3,463		(13,127)		(9,664)
Dividends to common stockholders—\$0.45 per share		_		10		_	(180,885)		_		(180,875)		_		(180,875)
Issuance of common stock for stock plans, restricted stock grants and other		141		30,378		_	_		(76)		30,443		_		30,443
Adjust redeemable OP unitholder interests to current fair value		_		(11,010)		_	_		_		(11,010)		_		(11,010)
Balance at June 30, 2023	\$	100,206	\$	15,584,858	\$	(14,552)	\$ (5,688,499)	\$	(13,631)	\$	9,968,382	\$	60,062	\$	10,028,444

VENTAS, INC. CONSOLIDATED STATEMENTS OF EQUITY

For the Six Months Ended June 30, 2024 and 2023 (In thousands, except per share amounts, unaudited)

For the Six Months Ended June 30, 2024

	Common tock Par Value	Capital in Excess of Par Value	Accumulated Other Comprehensive (Loss) Income	Retained Earnings (Deficit)	5	Freasury Stock	Total Ventas Stockholders' Equity	Noncontrolling Interests		To	otal Equity
Balance at January 1, 2024	\$ 100,648	\$ 15,650,734	\$ (35,757)	\$ (6,213,803)	\$	(13,764)	\$ 9,488,058	\$	56,347	\$	9,544,405
Net income	_	_	_	5,075		_	5,075		3,553		8,628
Other comprehensive income (loss)	_	_	18,348	_		_	18,348		(2,494)		15,854
Net change in noncontrolling interests	_	(19,199)	_	_		_	(19,199)		(9,040)		(28,239)
Dividends to common stockholders—\$0.45 per share	_	33	_	(368,667)		_	(368,634)		_		(368,634)
Issuance of common stock for stock plans, restricted stock grants and other	2,594	511,108	_	_		(11,296)	502,406		_		502,406
Adjust redeemable OP unitholder interests to current fair value	_	(5,108)	_	_		_	(5,108)		_		(5,108)
Redemption of OP Units		(1,596)	_				(1,596)				(1,596)
Balance at June 30, 2024	\$ 103,242	\$ 16,135,972	\$ (17,409)	\$ (6,577,395)	\$	(25,060)	\$ 9,619,350	\$	48,366	\$	9,667,716

For the Six Months Ended June 30, 2023

	Common tock Par Value	Capital in Excess of Par Value	Accumulated Other Comprehensive (Loss) Income	Retained Earnings (Deficit)		Treasury Stock		Total Ventas Stockholders' Equity	I	Noncontrolling Interests	Т	otal Equity
Balance at January 1, 2023	\$ 99,912	\$ 15,539,777	\$ (36,800)	\$ (5,449,385)	\$	(536)	\$	10,152,968	\$	68,709	\$	10,221,677
Net income	_	_	_	120,970		_		120,970		3,008		123,978
Other comprehensive income	_	_	22,248	_		_		22,248		2,731		24,979
Net change in noncontrolling interests	_	4,856	_	_		_		4,856		(14,386)		(9,530)
Dividends to common stockholders—\$0.90 per share	_	10	_	(360,084)		_		(360,074)		_		(360,074)
Issuance of common stock for stock plans, restricted stock grants and other	294	48,217	_	_		(13,095)		35,416		_		35,416
Adjust redeemable OP unitholder interests to current fair value	_	(7,933)	_	_		_		(7,933)		_		(7,933)
Redemption of OP Units	_	(69)	_					(69)		<u> </u>		(69)
Balance at June 30, 2023	\$ 100,206	\$ 15,584,858	\$ (14,552)	\$ (5,688,499)	\$	(13,631)	\$	9,968,382	\$	60,062	\$	10,028,444

VENTAS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited)

	 For the Six Months Ended June 3				
	 2024	2023			
Cash flows from operating activities:					
Net income	\$ 8,628 \$	123,978			
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation and amortization	640,103	586,808			
Amortization of deferred revenue and lease intangibles, net	(27,412)	(29,592)			
Other non-cash amortization	14,852	8,969			
Allowance on loans receivable and investments, net	(110)	(20,129)			
Stock-based compensation	22,076	20,389			
Straight-lining of rental income	(5,350)	(1,884)			
Loss (gain) on extinguishment of debt, net	672	(6,801)			
Gain on real estate dispositions	(50,011)	(11,606)			
Income tax expense (benefit)	1,378	(15,813)			
Loss (gain) from unconsolidated entities	10,035	(25,618)			
Gain on foreclosure of real estate	_	(29,127)			
Distributions from unconsolidated entities	10,063	9,682			
Other	129	(14,279)			
Changes in operating assets and liabilities:					
Increase in other assets	(16,523)	(17,341)			
Increase (decrease) in accrued interest	5,281	(3,524)			
Decrease in accounts payable and other liabilities	(11,491)	(19,468)			
Net cash provided by operating activities	602,320	554,644			
Cash flows from investing activities:	·	ŕ			
Net investment in real estate property	(325,244)	(977)			
Investment in loans receivable	(11,847)	(589)			
Proceeds from real estate disposals	238,091	64,405			
Proceeds from loans receivable	584	43,822			
Proceeds from sale of interest in unconsolidated entities	_	50,054			
Net cash assumed in foreclosure of real estate	_	11,615			
Development project expenditures	(164,828)	(144,809)			
Capital expenditures	(121,908)	(96,271)			
Investment in unconsolidated entities	(29,069)	(64,247)			
Insurance proceeds for property damage claims	2,834	9,390			
Net cash used in investing activities	 (411,387)	(127,607)			
Cash flows from financing activities:	(111,507)	(127,007)			
Net change in borrowings under revolving credit facilities	(10,770)	8,293			
Net change in borrowings under revolving electric tachnics Net change in borrowings under commercial paper program	(10,770)	(267,414)			
Proceeds from debt	1.216.336	1,748,532			
Repayment of debt	(1,405,872)	(1,489,112)			
Purchase of noncontrolling interests	(11,000)	(1,405,112)			
Payment of deferred financing costs	(29,147)	(27,356)			
Issuance of common stock, net	491,797	25,007			
Cash distribution to common stockholders	(365,163)	(361,703)			
Cash distribution to redeemable OP unitholders	(3,060)	(3,089)			
Cash issued for redemption of OP Units	(2,087)	(655)			
Contributions from noncontrolling interests	3,580	7,979			
Distributions to noncontrolling interests	(9,967)				
Proceeds from stock option exercises	(3,307)	(17,388) 1,736			
	(10.074)				
Other N. J. Committee of the Committee o	 (10,074)	(12,805)			
Net cash used in financing activities	 (135,427)	(388,085)			
Net increase in cash, cash equivalents and restricted cash	55,506	38,952			
Effect of foreign currency translation	(3,684)	650			
Cash, cash equivalents and restricted cash at beginning of period	 563,462	170,745			
Cash, cash equivalents and restricted cash at end of period	\$ 615,284 \$	210,347			

VENTAS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued) (In thousands, unaudited)

For the Six Months Ended June 30, 2024 Supplemental schedule of non-cash activities: Assets acquired and liabilities assumed from acquisitions and other: \$ 10,530 \$ Real estate investments 7,873 Other assets 1,171 Other liabilities 4,713 9,000 Deferred income tax liability 6,988 12,382 Settlement of loan receivable 486,082 Real estate received in settlement of loan receivable 1,566,395 Assumption of debt related to real estate owned 1,016,804

NOTE 1—DESCRIPTION OF BUSINESS

Ventas, Inc., (together with its consolidated subsidiaries, unless otherwise indicated or except where the context otherwise requires, "we," "our," "Company" and other similar terms) an S&P 500 company, is a real estate investment trust ("REIT") focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. We hold a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. As of June 30, 2024, we owned or had investments in approximately 1,350 properties (including properties classified as held for sale and unconsolidated properties). Our company is headquartered in Chicago, Illinois with additional corporate offices in Louisville, Kentucky and New York, New York.

We elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code (the "Code"), commencing with our taxable year ended December 31, 1999. Provided we qualify for taxation as a REIT, we generally will not be required to pay U.S. federal corporate income taxes on our REIT taxable income that is currently distributed to our stockholders. In order to maintain our qualification as a REIT, we must satisfy a number of highly technical requirements, which impact how we invest in, operate or manage our assets.

We primarily invest in our portfolio of real estate assets through wholly-owned subsidiaries and other co-investment entities. We operate through three reportable business segments: senior housing operating portfolio, which we also refer to as "SHOP," outpatient medical and research portfolio, which we also refer to as "OM&R," and triple-net leased properties. Non-segment assets consist primarily of corporate assets, including cash, restricted cash, loans receivable and investments and miscellaneous accounts receivable as well as investments in unconsolidated entities. In addition, from time to time, we make secured and unsecured loans and other investments relating to real estate or operators. Our chief operating decision maker evaluates performance of the combined properties in each operating segment and determines how to allocate resources to these segments, in significant part, based on net operating income ("NOI") and related measures for each segment. See "Note 16 – Segment Information." For a discussion of our definition of NOI and for a reconciliation of NOI to our net income attributable to common stockholders, as computed in accordance with U.S. generally accepted accounting principles ("GAAP"), see "Management's Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures."

We also have investments in unconsolidated entities, including through our third-party institutional capital management business, Ventas Investment Management ("VIM"). Through VIM, we partner with third-party institutional investors to invest in real estate through various joint ventures and other coinvestment vehicles where we are the sponsor or general partner, including our open-ended investment vehicle, the Ventas Life Science & Healthcare Real Estate Fund (the "Ventas Fund").

The following table summarizes information for our consolidated reportable business segments and non-segment assets for the six months ended June 30, 2024 (dollars in thousands):

Segment	Т	otal NOI (1)	Percentage of Total NOI	Number of Consolidated Properties
Senior housing operating portfolio (SHOP)	\$	417,724	41.0 %	582
Outpatient medical and research portfolio (OM&R)		291,842	28.7 %	428
Triple-net leased properties		302,058	29.7 %	308
Non-segment (2)		6,614	0.6 %	
	\$	1,018,238	100 %	1,318

^{(1) &}quot;NOI" is defined as total revenues, less interest and other income, property-level operating expenses and third party capital management expenses. See "Non-GAAP Financial Measures" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and a reconciliation of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

⁽²⁾ NOI for non-segment includes management fees and promote revenues, net of expenses related to our third-party institutional capital management business, income from loans and investments and various corporate-level expenses not directly attributable to any of our three reportable business segments.

NOTE 2—ACCOUNTING POLICIES

The accompanying Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information set forth in the Accounting Standards Codification ("ASC"), as published by the Financial Accounting Standards Board ("FASB"), and with the Securities and Exchange Commission ("SEC") instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of results for the interim period have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The accompanying Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"). Certain prior period amounts have been reclassified to conform to the current period presentation.

Accounting Estimates

The preparation of financial statements in accordance with GAAP requires us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying Consolidated Financial Statements include our accounts and the accounts of our wholly-owned subsidiaries and the joint venture entities over which we exercise control. All intercompany transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities ("VIEs"). Substantially all of the assets of the VIEs are real estate investments and substantially all of the liabilities of the VIEs are mortgage loans. Assets of the consolidated VIEs can only be used to settle obligations of such VIEs. Liabilities of the consolidated VIEs represent claims against the specific assets of the VIEs. Unless otherwise required by an operating agreement, any mortgage loans of the consolidated VIEs are non-recourse to us. The table below summarizes the total assets and liabilities of our consolidated VIEs as reported on our Consolidated Balance Sheets (dollars in thousands):

	As of Jun	e 30), 2024	As of December 31, 2023						
	 Total Assets	Total Liabilities	Total Assets		Total Liabilities					
NHP/PMB L.P.	\$ 748,205	\$	280,103	\$	759,817	\$	266,658			
Fonds Immobilier Groupe Maurice, S.E.C.	1,894,840		1,169,211		1,971,410		1,204,619			
Other identified VIEs	1,602,668		361,854		1,597,957		354,828			
Tax credit VIEs	27,879		4,400		29,746		4,024			

Recent Accounting Standards

In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires incremental disclosures related to a public entity's reportable segments. Required disclosures include, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount for other segment items (which is the difference between segment revenue less segment expenses and less segment profit or loss) and a description of its composition, the title and position of the CODM, and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The standard also permits disclosure of more than one measure of segment profit. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are evaluating the impact of adopting ASU 2023-07 and expect to have additional disclosures in our Form 10-K for the year ended December 31, 2024.

In December 2023, the FASB issued Accounting Standards Update 2023-09, *Improvements to Income Tax Disclosures* ("ASU 2023-09"), which requires public entities on an annual basis to (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. We are evaluating the impact of adopting ASU 2023-09 on our Consolidated Financial Statements.

In March 2024, the SEC adopted the final rule under SEC Release No. 33-11275, *The Enhancement and Standardization of Climate Related Disclosures for Investors*, which requires registrants to disclose climate-related information in registration statements and annual reports. The new rules would be effective for annual reporting periods beginning in fiscal year 2025. However, in April 2024, the SEC exercised its discretion to stay these rules pending the completion of judicial review of certain consolidated petitions with the United States Court of Appeals for the Eighth Circuit in connection with these rules. We are evaluating the impact of this rule on our Consolidated Financial Statements.

NOTE 3—CONCENTRATION OF CREDIT RISK

The properties managed by Atria Senior Living, Inc. (together with its subsidiaries, including Holiday Retirement ("Holiday"), "Atria") and Sunrise Senior Living, LLC (together with its subsidiaries, "Sunrise"), and leased to Brookdale Senior Living Inc. (together with its subsidiaries, "Brookdale"), Ardent Health Partners, Inc. (f/k/a Ardent Health Partners, LLC and, together with its subsidiaries, "Ardent") and Kindred Healthcare, LLC (together with its subsidiaries, "Kindred") contributed approximately 19.2%, 5.9%, 7.2%, 6.6% and 6.6%, respectively, of our total NOI for the three months ended June 30, 2024. Because Atria and Sunrise manage our properties in exchange for a management fee from us, we are not directly exposed to their credit risk in the same manner or to the same extent as triple-net tenants like Brookdale, Ardent and Kindred.

Our SHOP, outpatient medical and research portfolio and triple-net leased properties segments contributed 41.7%, 28.4%, and 29.2%, respectively, of our total NOI for the three months ended June 30, 2024. Our consolidated properties were located in 47 states, the District of Columbia, seven Canadian provinces and the United Kingdom as of June 30, 2024, with properties in one state (California) accounting for more than 10% of our total consolidated revenues and NOI for each of the three months ended June 30, 2024 and 2023. See "Non-GAAP Financial Measures" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and a reconciliation of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

Triple-Net Leased Properties

The properties we triple-net leased to Brookdale, Ardent and Kindred accounted for a significant portion of total revenues and total NOI for the three months ended June 30, 2024 and 2023. The following table reflects the concentration risk related to our triple-net leased properties including assets held for sale for the periods presented:

	For the Three Months Ended June 30,					
	2024	2023				
Contribution as a Percentage of Total Revenues (1):						
Brookdale	3.1 %	3.4 %				
Ardent (2)	2.8	3.0				
Kindred	2.8	3.0				
Contribution as a Percentage of Total NOI (3):						
Brookdale	7.2 %	7.8 %				
Ardent (2)	6.6	6.9				
Kindred	6.6	6.9				

⁽¹⁾ Total revenues include third party capital management revenues, income from loans and investments and interest and other income.

⁽²⁾ Results exclude 19 outpatient medical buildings included in our outpatient medical and research portfolio segment.

⁽³⁾ See "Non-GAAP Financial Measures" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and a reconciliation of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

Each of our leases with Brookdale, Ardent and Kindred is a triple-net lease that obligates the tenant to pay all property-related expenses, including maintenance, utilities, repairs, taxes, insurance and capital expenditures, and to comply with the terms of the mortgage financing documents, if any, affecting the properties. In addition, each of our Brookdale, Ardent and Kindred leases is guaranteed by a corporate parent.

Kindred Lease

As of June 30, 2024, we leased 29 properties to Kindred (collectively, the "Kindred Portfolio") pursuant to a single, triple-net master lease agreement (together with certain other agreements related to such master lease, collectively, the "Kindred Lease"). The Kindred Portfolio is divided into two separate renewal groups. The first group is composed of six properties ("Group 1") and the second group is composed of 23 properties ("Group 2"). As of June 30, 2024, the Kindred Lease represented approximately 6.6% of the Company's total annualized NOI, with Group 1 representing approximately 1.3% of total annualized NOI and Group 2 representing approximately 5.3% of the Company's total annualized NOI. Kindred's obligations under the Kindred Lease are guaranteed by a parent company.

The current term of the Kindred Lease for Group 1 expires on April 30, 2028. Under the Kindred Lease, Kindred has the option to renew the lease for all of the properties (but not less than all) within Group 1 for two 5-year extensions, in each case at the greater of escalated rent and fair market rent, by providing written notice no later than one year prior to the applicable expiration date.

The current term of the Kindred Lease for Group 2 expires on April 30, 2025. Under the Kindred Lease, Kindred had the option to renew the lease for all of the properties (but not less than all) within Group 2 for three 5-year extensions, in each case at the greater of escalated rent and fair market rent, by providing written notice no later than one year prior to the applicable expiration date. Although Kindred did not provide such notice, we and Kindred could still reach a negotiated agreement to extend the Kindred Lease with respect to some or all of the Group 2 properties. For any properties that Kindred does not continue to lease, there are other options we may choose to pursue, including, without limitation, transitions to replacement operators, conversions of properties to alternative uses and sale transactions. There can be no assurance that any negotiated agreement we reach with Kindred or any other options we may pursue with respect to the Group 2 properties would be as favorable to us as the current Kindred Lease.

If the Kindred Lease is renewed or otherwise extended for some or all of the Group 2 properties, the total contractual cash rent for those properties for the period from the date of the renewal or extension agreement to the end of the new or extended lease term would be straightlined for accounting purposes. If in such renewal or extension agreement we were to agree to continue to lease to Kindred some or all of the Group 2 properties after the current expiration date of April 30, 2025 for a lower base rent than the rent currently in place for such properties, we would recognize a non-cash GAAP reduction in revenue during the period after we reach such agreement through April 30, 2025 even if existing contractual cash rent remains unchanged and is fully paid at such higher level prior to such date.

Since the COVID-19 pandemic began to recede, the financial performance of the Kindred Portfolio has declined such that financial performance for the trailing 12-month period ending June 30, 2024 does not exceed the rent under the Kindred Lease for such period. While we believe that Kindred has taken and is taking targeted actions to attempt to improve the performance of the properties, there can be no assurance that Kindred will be able to do so or that such financial performance will not affect Kindred's ability to perform its obligations to us or impact any of its decisions related to the renewal of the lease. We believe there are many factors in addition to portfolio coverage that will influence the ultimate outcome as it relates to the Group 2 properties.

See "Part I—Item 1A. Risk Factors—Risks Related to Our Business Operations and Strategy—If we need to replace any of our tenants or managers, we may be unable to do so on as favorable terms, if at all, and we could be subject to delays, limitations and expenses, which could adversely affect our business, financial condition and results of operations." "Part I—Item 1A. Risk Factors—Risks Related to Our Business Operations and Strategy—A significant portion of our revenues and operating income is dependent on a limited number of tenants and managers, including Brookdale, Ardent, Kindred, Atria and Sunrise." and "Part I—Item 1A. Risk Factors—Risks Related to Our Business Operations and Strategy—We face potential adverse consequences from the bankruptcy, insolvency or financial deterioration of our tenants, managers, borrowers and other obligors." in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Brookdale Lease

As of June 30, 2024, we leased 121 properties (excluding 10 properties managed by Brookdale pursuant to long-term management agreements and included in the SHOP segment) to Brookdale pursuant to a single, triple-net master lease agreement (together with certain other agreements related to such master lease, collectively, the "Brookdale Lease"). The aggregate cash base rent due to us from Brookdale in 2024 is approximately \$110.3 million, and the current aggregate contractual base rent (computed in accordance with GAAP) is approximately \$148.9 million. The difference between the aggregate cash base rent due in 2024 and the current aggregate contractual base rent (computed in accordance with GAAP) is, in part, a result of the amortization over the remaining lease term of \$235 million of up-front consideration received as part of amendments to the Brookdale Lease that were entered into in July 2020 (the "2020 Consideration"). The 2020 Consideration consisted of: (a) \$162 million in cash; (b) a \$45 million note (repaid by Brookdale in 2021); and (c) \$28 million, representing the initial value of warrants exercisable for 16.3 million shares of Brookdale Senior Living, Inc. common stock. As of June 30, 2024, approximately \$170.6 million of such 2020 Consideration has been amortized, leaving approximately \$64.0 million unamortized. The Brookdale Lease is guaranteed by Brookdale Senior Living, Inc.

Under the terms of the Brookdale Lease, base rent escalates annually at 3% per annum, commencing on January 1, 2022. The term of the Brookdale Lease expires December 31, 2025. Brookdale has the option to renew the Brookdale Lease with respect to all (but not less than all) of the properties for two, 10-year extensions. Base rent for the first year of each extension is the greater of (a) 103% of prior full year's base rent; and (b) fair market rent, capped at a 10% increase. Subsequent to the first year of any such renewal, base rent would continue to escalate by 3% per annum over the prior full year's base rent.

Brookdale currently has the option to renew the Brookdale Lease for its next 10-year extension by providing written notice to us after June 30, 2024 and on or before November 30, 2024. If Brookdale does not timely exercise its renewal option, we and Brookdale may nonetheless reach a negotiated agreement to continue the Brookdale Lease in whole or in part prior to its expiration date. If all or any part of the Brookdale Lease is renewed or otherwise extended, the then remaining unamortized portion of the 2020 Consideration would be re-amortized and the new GAAP rent for the period from the date of the renewal or extension agreement to the end of the new or extended lease term would be straightlined. See "Risk Factors—Risks Related to Our Business Operations and Strategy—If we need to replace any of our tenants or managers, we may be unable to do so on as favorable terms, if at all, and we could be subject to delays, limitations and expenses, which could adversely affect our business, financial condition and results of operations." and "Risk Factors—Risks Related to Our Business Operations and Strategy—A significant portion of our revenues and operating income is dependent on a limited number of tenants and managers, including Brookdale, Ardent, Kindred, Atria and Sunrise." included in Part 1, Item 1A in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

During the three months ended June 30, 2024, we exercised warrants for 1.7 million shares of Brookdale Senior Living, Inc. common stock ("Brookdale Common Stock") on a cashless basis, resulting in our receipt of 0.9 million shares of Brookdale Common Stock (net of the \$3.00 exercise price), which we sold for net cash proceeds of \$6.1 million (recorded within operating cashflows in our Consolidated Statements of Cash Flows). We recognized a \$1.0 million net realized loss relative to the fair market value of the warrants as of March 31, 2024 (recorded in Other Expense in our Consolidated Statements of Income). As of June 30, 2024, we continued to hold 14.6 million warrants for Brookdale Common Stock, which are exercisable at any time prior to December 31, 2025 and have an exercise price of \$3.00 per share. The remaining warrants are classified within Other Assets on our Consolidated Balance Sheets and measured at fair value with changes in fair value being recognized within Other Expense in our Consolidated Statements of Income.

Ardent Lease

As of June 30, 2024, we leased 11 properties (excluding 19 outpatient medical buildings leased to Ardent under separate leases included in our outpatient medical and research portfolio segment) to Ardent pursuant to a single, triple-net master lease agreement (together with certain other agreements related to such master lease, collectively, the "Ardent Lease"). The existing term of the Ardent Lease expires August 31, 2035 and Ardent has the option to renew such term for one, 10-year extension at contractual escalated rent. The Ardent Lease is guaranteed by the Ardent parent company. In July 2024, Ardent Health Partners, Inc., the parent company of the tenants under, and guarantor of, the Ardent Lease, consummated an initial public offering (the "Ardent IPO"). See "Note 7 – Investments in Unconsolidated Entities."

Senior Housing Operating Portfolio

As of June 30, 2024, Atria and Sunrise, collectively, provided comprehensive property management and accounting services with respect to 298 of our 582 consolidated senior housing communities, for which we pay annual management fees pursuant to long-term management agreements.

As of June 30, 2024, Atria managed a pool of 205 senior housing communities for Ventas. Ventas has the right to terminate the management contract for 57 of the communities on short notice.

As of June 30, 2024, Sunrise managed 93 senior housing communities for Ventas pursuant to multiple management agreements (collectively, the "Sunrise Management Agreements"). Our Sunrise Management Agreements have initial terms expiring between 2034 and 2040. Ventas has the ability to terminate some or all of the Sunrise Management Agreements under certain circumstances with or without the payment of a fee.

We rely on our managers' personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment to manage our senior housing operating portfolio efficiently and effectively. We also rely on our managers to set appropriate resident fees, provide accurate property-level financial results in a timely manner and otherwise operate our senior housing communities in compliance with the terms of our management agreements and all applicable laws and regulations.

NOTE 4—ACQUISITIONS OF REAL ESTATE PROPERTY

We acquire and invest in senior housing, outpatient medical buildings, research centers and other healthcare properties primarily to achieve an expected yield on our investment, to grow and diversify our portfolio and revenue base, and to reduce our dependence on any single tenant, operator or manager, geographic location, asset type, business model or revenue source. Each of our acquisitions disclosed below was accounted for as an asset acquisition.

2024 Acquisitions

During the six months ended June 30, 2024, we acquired 11 senior housing communities reported within our SHOP segment for an aggregate purchase price of \$327.4 million.

NOTE 5—DISPOSITIONS AND IMPAIRMENTS

2024 Activity

During the six months ended June 30, 2024, we sold 15 senior housing communities, 10 outpatient medical buildings (one of which was vacant) and 23 triple-net leased properties for aggregate consideration of \$234.1 million and recognized a gain on the sale of these assets of \$50.0 million in our Consolidated Statements of Income.

Assets Held for Sale

The table below summarizes our real estate assets classified as held for sale including the amounts reported on our Consolidated Balance Sheets, which may include anticipated post-closing settlements of working capital for disposed properties (dollars in thousands):

		f June 30, 2024		As of December 31, 2023						
	Number of Properties Held Assets Held for Sale Sale Liabilities Related to Asset Held for Sale		lated to Assets	Number of Properties Held for Sale		sets Held for Sale		Liabilities ated to Assets leld for Sale		
SHOP	3	\$	18,725	\$	3,515	13	\$	48,173	\$	6,419
Outpatient medical and research portfolio (1)	_		24,536		1,473	3		5,431		2,643
Triple-net leased properties	_		_		_	1		2,885		181
Total	3	\$	43,261	\$	4,988	17	\$	56,489	\$	9,243

The balances as of June 30, 2024 relate to a partial sale of a building, as such, no property count is allocated.

Real Estate Impairments

We recognized impairments of \$44.9 million and \$10.7 million for the three months ended June 30, 2024 and 2023, respectively, and \$50.3 million and \$19.2 million for the six months ended June 30, 2024 and 2023 respectively, which are recorded primarily as a component of depreciation and amortization in our Consolidated Statements of Income. The impairments recorded were primarily a result of a change in our intent to hold or a change in the expected future cash flows of the impaired assets.

NOTE 6—LOANS RECEIVABLE AND INVESTMENTS

As of June 30, 2024 and December 31, 2023, we held \$65.5 million and \$54.1 million, respectively, of loans receivable and investments, net of allowance, relating to senior housing and healthcare operators or properties. The following is a summary of our loans receivable and investments, net, including amortized cost, fair value and unrealized gains or losses on available for sale investments, if applicable (dollars in thousands):

		Amortized Cost		Allowance		Carrying Amount		Fair Value	
As of June 30, 2024:	_								
Secured/mortgage loans and other, net (1)	•	\$	36,195	\$	_	\$	36,195	\$ 36,248	
Non-mortgage loans receivable, net (2)			33,213		(3,866)		29,347	28,314	
Total loans receivable and investments, net	3	\$	69,408	\$	(3,866)	\$	65,542	\$ 64,562	
	-		•						
As of December 31, 2023:									
Secured/mortgage loans and other, net (1)		\$	27,986	\$	_	\$	27,986	\$ 27,947	
Non-mortgage loans receivable, net (2)			30,128		(3,976)		26,152	25,200	
Total loans receivable and investments, net	•	\$	58,114	\$	(3,976)	\$	54,138	\$ 53,147	

⁽¹⁾ Investments have contractual maturities ranging from 2024 to 2027.

⁽²⁾ Included in other assets on our Consolidated Balance Sheets.

NOTE 7—INVESTMENTS IN UNCONSOLIDATED ENTITIES

We report investments in unconsolidated entities over whose operating and financial policies we have the ability to exercise significant influence under the equity method of accounting. We are not required to consolidate these entities because our joint venture partners have significant participating rights, nor are these entities considered VIEs, as they are controlled by equity holders with sufficient capital. Our investments in unconsolidated entities include investments in both real estate entities and operating entities as described further below.

Investments in Unconsolidated Real Estate Entities

Below is a summary of our investments in unconsolidated real estate entities, including through VIM, as of June 30, 2024 and December 31, 2023, respectively (dollars in thousands):

	Owners	hip as of ⁽¹⁾		Carrying A	Amount as of		
	June 30, 2024	0, 2024 December 31, 2023		ne 30, 2024	Decei	mber 31, 2023	
Investments in unconsolidated real estate entities:							
Ventas Life Science & Healthcare Real Estate Fund	20.1%	20.1%	\$	262,374	\$	264,442	
Pension Fund Joint Venture	25.0%	25.0%		19,125		22,169	
Research & Innovation Development Joint Venture	53.0%	53.0%		290,619		275,829	
Ventas Investment Management platform				572,118		562,440	
Atrium Health & Wake Forest Joint Venture	48.5%	48.5%		36,112		35,137	
All other (2)	34.0%-37.5%	34.0%-37.5%		614		629	
Total investments in unconsolidated real estate entities			\$	608,844	\$	598,206	

⁽¹⁾ The entities in which we have an ownership interest may have less than a 100% interest in the underlying real estate. The ownership percentages in the table reflect our interest in the entities. Joint venture members, including us in some instances, have equity participation rights based on the underlying performance of the investments, which could result in non pro rata distributions.

We provide various services to our unconsolidated real estate entities in exchange for fees and reimbursements. Total management fees earned in connection with these services were \$3.9 million and \$3.6 million for the three months ended June 30, 2024 and 2023, respectively, and \$7.7 million and \$7.2 million for the six months ended June 30, 2024 and 2023, respectively. Such amounts, along with any promote revenue, are included in third party capital management revenues in our Consolidated Statements of Income.

Investments in Unconsolidated Operating Entities

We own investments in unconsolidated operating entities such as Ardent and Atria, which are included within other assets on our Consolidated Balance Sheets.

As of June 30, 2024, we held a 34% ownership interest in Atria, which entitles us to customary minority rights and protections, including the right to appoint two members to the Atria Board of Directors.

As of June 30, 2024, we held a 7.5% ownership interest in Ardent, which entitled us to customary minority rights and protections, including the right to appoint one member to the Ardent Board of Directors. Following Ardent's initial public offering, which was consummated in July 2024 (the "Ardent IPO"), we held an approximately 6.5% ownership interest in Ardent. In connection with the Ardent IPO, we entered into a nomination agreement with Ardent, which provides us the right (but not the obligation) to nominate one member of the Ardent Board of Directors for so long as we beneficially own 4% or more of the total voting power of Ardent.

⁽²⁾ Includes investments in parking structures and other de minimis investments in unconsolidated real estate entities.

NOTE 8—INTANGIBLES

The following is a summary of our intangibles (dollars in thousands):

		As of June	30, 2024	As of December 31, 2023					
	Weighted Average Remaining Amortization Balance Period in Years			Balance	Weighted Average Remaining Amortization Period in Years				
Intangible assets:									
Above-market lease intangibles (1)	\$	128,773	4.5	\$	130,371	4.8			
In-place and other lease intangibles (2)		1,325,700	9.3		1,317,775	8.3			
Goodwill		1,045,071	N/A		1,045,176	N/A			
Other intangibles (2)		34,389	4.3		34,440	4.8			
Accumulated amortization		(1,253,521)	N/A		(1,189,817)	N/A			
Net intangible assets	\$	1,280,412	8.8	\$	1,337,945	8.0			
Intangible liabilities:		_							
Below-market lease intangibles (1)	\$	306,094	7.8	\$	306,499	8.1			
Other lease intangibles		13,498	N/A		13,498	N/A			
Accumulated amortization		(246,908)	N/A		(241,600)	N/A			
Purchase option intangibles		3,568	N/A		3,568	N/A			
Net intangible liabilities	\$	76,252	7.8	\$	81,965	8.1			

⁽¹⁾ Amortization of above- and below-market lease intangibles is recorded as a decrease and an increase to revenues, respectively, in our Consolidated Statements of Income.

N/A-Not Applicable

Above-market lease intangibles and in-place and other lease intangibles are included in acquired lease intangibles within real estate investments on our Consolidated Balance Sheets. Other intangibles (including non-compete agreements, trade names and trademarks) are included in other assets on our Consolidated Balance Sheets. Below-market lease intangibles, other lease intangibles and purchase option intangibles are included in accounts payable and other liabilities on our Consolidated Balance Sheets.

⁽²⁾ Amortization of lease intangibles is recorded in depreciation and amortization in our Consolidated Statements of Income.

NOTE 9—OTHER ASSETS

The following is a summary of our other assets (dollars in thousands):

	As of June 30, 2024	As of December 31, 2023
Straight-line rent receivables	\$ 198,668	\$ 194,108
Deferred lease costs, net	130,862	118,556
Investment in unconsolidated operating entities	77,880	80,312
Stock warrants	61,100	59,281
Non-mortgage loans receivable, net	29,347	26,152
Other intangibles, net	5,153	5,584
Other	199,976	 199,417
Total other assets	\$ 702,986	\$ 683,410

Stock warrants represent warrants exercisable at any time prior to December 31, 2025, in whole or in part, for 14.6 million shares of Brookdale Senior Living, Inc. common stock at an exercise price of \$3.00 per share. See Note 3 – Concentration of Credit Risk. The remaining warrants are measured at fair value with changes in fair value being recognized within Other Expense in our Consolidated Statements of Income.

NOTE 10—SENIOR NOTES PAYABLE AND OTHER DEBT

The following is a summary of our senior notes payable and other debt (dollars in thousands):

	As of June 30, 2024	As of December 31, 2023
Unsecured revolving credit facility (1)(2)	\$ 3,161	\$ 14,006
Commercial paper notes	<u> </u>	
3.50% Senior Notes due 2024	<u> </u>	400,000
3.75% Senior Notes due 2024	<u> </u>	400,000
4.125% Senior Notes, Series B due 2024 (2)	119,362	123,256
2.80% Senior Notes, Series E due 2024 (2)	<u> </u>	55,143
Unsecured term loan due 2025 (2)	<u> </u>	377,501
3.50% Senior Notes due 2025	600,000	600,000
2.65% Senior Notes due 2025	450,000	450,000
4.125% Senior Notes due 2026	500,000	500,000
3.25% Senior Notes due 2026	450,000	450,000
3.75% Exchangeable Senior Notes due 2026	862,500	862,500
Unsecured term loan due February 2027	200,000	200,000
Unsecured term loan due June 2027	500,000	500,000
2.45% Senior Notes, Series G due 2027 (2)	347,298	358,626
3.85% Senior Notes due 2027	400,000	400,000
4.00% Senior Notes due 2028	650,000	650,000
5.398% Senior Notes, Series I due 2028 (2)	438,693	453,001
4.40% Senior Notes due 2029	750,000	750,000
5.10% Senior Notes, Series J due 2029 (2)	475,250	<u> </u>
3.00% Senior Notes due 2030	650,000	650,000
4.75% Senior Notes due 2030	500,000	500,000
2.50% Senior Notes due 2031	500,000	500,000
3.30% Senior Notes, Series H due 2031 (2)	219,346	226,501
5.625% Senior Note due 2034	500,000	_
6.90% Senior Notes due 2037 (3)	52,400	52,400
6.59% Senior Notes due 2038 ⁽³⁾	21,413	21,413
5.70% Senior Notes due 2043	300,000	300,000
4.375% Senior Notes due 2045	300,000	300,000
4.875% Senior Notes due 2049	300,000	300,000
Mortgage loans and other	3,186,118	3,174,251
Total	13,275,541	13,568,598
Deferred financing costs, net	(99,445)	(84,034)
Unamortized fair value adjustment	(15,516)	17,081
Unamortized discounts	14,497	(10,749)
Senior notes payable and other debt	\$ 13,175,077	\$ 13,490,896

⁽¹⁾ As of June 30, 2024 and December 31, 2023, respectively, no aggregate borrowings were denominated in Canadian dollars. Aggregate borrowings of \$3.2 million and \$14.0 million were denominated in British pounds as of June 30, 2024 and December 31, 2023, respectively.

⁽²⁾ British Pound and Canadian Dollar debt obligations shown in US Dollars.

Our 6.90% Senior Notes due 2037 are subject to repurchase at the option of the holders, at par, on October 1, 2027, and our 6.59% Senior Notes due 2038 are subject to repurchase at the option of the holders, at par, on July 7, 2028.

Credit Facilities, Commercial Paper, Unsecured Term Loans and Letters of Credit

As of June 30, 2024, we have a \$2.75 billion unsecured revolving credit facility priced at SOFR plus 0.10% applied in connection with the transition from LIBOR to SOFR ("Adjusted SOFR") plus 0.775% which is subject to adjustment based on the Company's debt ratings. Our unsecured revolving credit facility matures in April 2028, and may be extended at our option, subject to the satisfaction of certain conditions, for two additional periods of six months each. The revolving credit facility also includes an accordion feature that permits us to increase our aggregate borrowing capacity thereunder to up to \$3.75 billion, subject to the satisfaction of certain conditions, including the receipt of additional commitments for such increase.

Our unsecured revolving credit facility imposes certain customary restrictions on us, including restrictions pertaining to: (i) liens; (ii) investments; (iii) the incurrence of additional indebtedness; (iv) mergers and dissolutions; (v) certain dividend, distribution and other payments; (vi) permitted businesses; (vii) transactions with affiliates; and (viii) the maintenance of certain consolidated total leverage, secured debt leverage, unsecured debt leverage and fixed charge coverage ratios and minimum consolidated adjusted net worth, and contains customary events of default.

As of June 30, 2024, we had \$2.7 billion of undrawn capacity under our unsecured revolving credit facility with \$3.2 million outstanding and an additional \$0.8 million restricted to support outstanding letters of credit. We use our unsecured revolving credit facility to support our commercial paper program and for general corporate purposes.

Our wholly-owned subsidiary, Ventas Realty, Limited Partnership ("Ventas Realty"), may issue from time to time unsecured commercial paper notes up to a maximum aggregate amount outstanding at any time of \$1.0 billion. The notes are sold under customary terms in the U.S. commercial paper note market and are ranked pari passu with all of Ventas Realty's other unsecured senior indebtedness. The notes are fully and unconditionally guaranteed by Ventas, Inc. As of June 30, 2024, we had no borrowings outstanding under our commercial paper program.

Ventas Realty has a \$500.0 million unsecured term loan priced at Adjusted SOFR plus 0.85%, which is subject to adjustment based on Ventas Realty's debt ratings. This term loan is fully and unconditionally guaranteed by Ventas, Inc. It matures in June 2027 and includes an accordion feature that permits Ventas Realty to increase the aggregate borrowings thereunder to up to \$1.25 billion, subject to the satisfaction of certain conditions, including the receipt of additional commitments for such increase.

Ventas Realty has a \$200.0 million unsecured term loan priced at Adjusted SOFR plus 0.85%, which is subject to adjustment based on Ventas Realty's debt ratings. This term loan is fully and unconditionally guaranteed by Ventas, Inc. It matures in February 2027 and includes an accordion feature that permits Ventas Realty to increase the aggregate borrowings thereunder to up to \$500.0 million, subject to the satisfaction of certain conditions, including the receipt of additional commitments for such increase.

During the six months ended June 30, 2024, we repaid and extinguished a C\$500.0 million or \$367.9 million unsecured term loan facility priced at Canadian Dollar Offered Rate ("CDOR") plus 0.90% that would otherwise have matured in January 2025. We also repaid C\$73.0 million or \$53.4 million aggregate principal amount of 2.80% Senior Notes, Series E due 2024 at maturity.

As of June 30, 2024, our \$100.0 million uncommitted line for standby letters of credit had an outstanding balance of \$14.7 million. The agreement governing the line contains certain customary covenants and, under its terms, we are required to pay a commission on each outstanding letter of credit at a fixed rate.

Exchangeable Senior Notes

In June 2023, Ventas Realty issued \$862.5 million aggregate principal amount of its 3.75% Exchangeable Senior Notes due 2026 (the "Exchangeable Notes") in a private placement. The Exchangeable Notes are senior, unsecured obligations of Ventas Realty and are fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Ventas, Inc. The Exchangeable Notes bear interest at a rate of 3.75% per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2023. The Exchangeable Notes mature on June 1, 2026, unless earlier exchanged, redeemed or repurchased. As of June 30, 2024, we had \$862.5 million aggregate principal amount of the Exchangeable Notes outstanding. During the three and six months ended June 30, 2024, we recognized approximately \$8.1 million and \$16.2 million respectively, of contractual interest expense and amortization of issuance costs of \$1.7 million and \$3.4 million, respectively,

related to the Exchangeable Notes. Unamortized issuance costs of \$13.7 million as of June 30, 2024 were recorded as an offset to senior notes payable and other debt on our Consolidated Balance Sheet.

The Exchangeable Notes are exchangeable at an initial exchange rate of 18.2460 shares of our common stock per \$1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately \$54.81 per share of common stock). The initial exchange rate is subject to adjustment, including in the event of the payment of a quarterly dividend in excess of \$0.45 per share, but will not be adjusted for any accrued and unpaid interest. Upon exchange of the Exchangeable Notes, Ventas Realty will pay cash up to the aggregate principal amount of the Exchangeable Notes to be exchanged and pay or deliver (or cause to be delivered), as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at Ventas Realty's election, in respect of the remainder, if any, of its exchange obligation in excess of the aggregate principal amount of the Exchangeable Notes being exchanged. Prior to the close of business on the business day immediately preceding March 1, 2026, the Exchangeable Notes will be exchangeable at the option of the noteholders only upon the satisfaction of specified conditions and during certain periods described in the indenture governing the Exchangeable Notes. On or after March 1, 2026, until the close of business on the business day immediately preceding the maturity date, the Exchangeable Notes will be exchangeable at the option of the noteholders at any time regardless of these conditions or periods.

We have evaluated and concluded that the exchange options embedded in our exchangeable senior notes are eligible for the entity's own equity scope exception from ASC 815 and therefore, do not need to be bifurcated. Accordingly, we record our exchangeable senior notes as liabilities (included in senior notes payable and other debt on our Consolidated Balance Sheets).

Senior Notes

In February 2024, Ventas Canada Finance Limited ("Ventas Canada") issued and sold \$475.3 million (C\$650.0 million) aggregate principal amount of 5.10% Senior Notes, Series J due 2029 in a private placement. The proceeds were primarily used to repay a \$367.9 million (C\$500.0 million) unsecured term loan facility due 2025.

In April and May 2024, we repaid \$800.0 million senior notes consisting of \$400.0 million aggregate principal amount of 3.50% Senior Notes due 2024 and \$400.0 million aggregate principal amount of 3.75% Senior Notes due 2024 at maturity primarily with cash on hand and through our commercial paper program.

In April 2024, we repaid \$53.4 million (C\$73.0 million) aggregate principal amount of 2.80% Senior Notes, Series E due 2024 at maturity with cash on hand.

In May 2024, Ventas Realty issued and sold \$500.0 million aggregate principal amount of 5.625% Senior Notes due 2034 in a registered public offering. The proceeds were primarily used to repay balances outstanding under our commercial paper program.

Mortgages

In February 2024, we entered into a C\$52.8 million fixed rate mortgage loan, which accrues interest at 4.644%, matures in 2029 and is secured by one senior housing community in Canada.

In April 2024, we entered into an aggregate C\$103.0 million fixed rate mortgage loans, which accrue interest at a blended rate of 4.90%, mature in 2029 and are secured by two senior housing communities in Canada.

In May 2024, we entered into a \$52.3 million fixed rate mortgage loan, which accrues interest at 6.02%, matures in 2034 and is secured by one outpatient medical building in California.

Scheduled Maturities of Borrowing Arrangements and Other Provisions

As of June 30, 2024, our indebtedness had the following maturities (dollars in thousands):

	Principal Amount Due at Maturity	Unsecured Revolving Credit Facility and Commercial Paper Notes Scheduled Periodic Amortization			Total Maturities
2024	\$ 190,188	\$ _	\$	27,231	\$ 217,419
2025	1,811,753	_		48,623	1,860,376
2026	1,930,699	_		42,769	1,973,468
2027	1,562,551	_		42,947	1,605,498
2028	1,481,389	3,161		35,986	1,520,536
Thereafter	5,968,500	_		129,744	6,098,244
Total maturities	\$ 12,945,080	\$ 3,161	\$	327,300	\$ 13,275,541

Derivatives and Hedging

In the normal course of our business, interest rate fluctuations affect future cash flows under our variable rate debt obligations, loans receivable and marketable debt securities, and foreign currency exchange rate fluctuations affect our operating results. We follow established risk management policies and procedures, including the use of derivative instruments, to mitigate the impact of these risks.

We do not use derivative instruments for trading or speculative purposes, and we have a policy of entering into contracts only with major financial institutions based upon their credit ratings and other factors. When considered together with the underlying exposure that the derivative is designed to hedge, we do not expect that the use of derivatives in this manner would have any material adverse effect on our future financial condition or results of operations.

Periodically, we enter into and designate interest rate locks to partially hedge the risk of changes in interest payments attributable to increases in the benchmark interest rate during the period leading up to the probable issuance of fixed-rate debt. We designate our interest rate locks as cash flow hedges. Gains and losses when we settle our interest rate locks are amortized into earnings over the life of the related debt, except where a material amount is deemed to be ineffective, which would be immediately recognized in the Consolidated Statements of Income.

As of June 30, 2024, our variable rate debt obligations of \$0.7 billion reflect, in part, the effect of \$142.3 million notional amount of interest rate swaps with maturities in March 2027, that effectively convert fixed rate debt to variable rate debt.

As of June 30, 2024, our fixed rate debt obligations of \$12.5 billion reflect, in part, the effect of \$526.9 million and C\$643.8 million notional amount of interest rate swaps with maturities ranging from February 2025 to April 2031, in each case, that effectively convert variable rate debt to fixed rate debt.

2024 Activity

In June through August 2024, we entered into an aggregate \$200.0 million treasury locks to hedge interest rate risk on future debt issuances. The treasury locks expire in June and July 2025 and fix the 10-year U.S. treasury at 4.1%.

NOTE 11—FAIR VALUES OF FINANCIAL INSTRUMENTS

Overview

Accounting guidance on fair value measurements for certain financial assets and liabilities requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following categories:

• Level 1: Fair value calculated based on unadjusted quoted prices for identical assets or liabilities in active markets that we have the ability to access.

- Level 2: Fair value calculated using inputs other than quoted prices included in level one that are directly or indirectly observable for the asset or liability. Level two inputs may include quoted prices for similar assets and liabilities in active markets and other inputs for the asset or liability that are observable at commonly quoted intervals, such as interest rates, foreign exchange rates and yield curves.
- Level 3: Fair value calculated using unobservable inputs for the asset or liability, which typically are based on our own assumptions, because there is little, if any, related market activity.

The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. Accordingly, the estimates presented are not necessarily indicative of the amounts we would realize in a current market exchange or transaction.

Financial Instruments Measured at Fair Value

The table below summarizes the carrying amounts and fair values of our financial instruments either recorded or disclosed on a recurring basis (dollars in thousands):

	As of Jun	2024	As of December 31, 2023				
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:					_		
Cash and cash equivalents (1)	\$ 557,082	\$	557,082	\$	508,794	\$	508,794
Escrow deposits and restricted cash (1)	58,202		58,202		54,668		54,668
Stock warrants (3)(5)	61,100		61,100		59,281		59,281
Secured mortgage loans and other, net (3)(4)	36,195		36,248		27,986		27,947
Non-mortgage loans receivable, net (3)(4)(5)	29,347		28,314		26,152		25,200
Derivative instruments (3)(5)	26,445		26,445		19,782		19,782
Liabilities:							
Senior notes payable and other debt, gross (3)(4)	13,275,541		12,770,607		13,568,598		13,104,091
Derivative instruments (3)(6)	919		919		2,525		2,525
Redeemable OP Units (2)	175,076		175,076		173,452		173,452

The carrying amount approximates fair value due to the short maturity of these instruments.

Other Items Measured at Fair Value on a Nonrecurring Basis

Real estate recorded as held for sale and any associated real estate impairment recorded due to the shortening of the expected hold period due to our change in intent to hold the asset (see "Note 5 – Dispositions and Impairments") are measured at fair value on a nonrecurring basis. We estimate the fair value of assets held for sale and any associated impairment charges based primarily on current sales price expectations, which reside within Level 2 of the fair value hierarchy.

Real estate impairment charges recorded due to our evaluation of recoverability when events or changes in circumstances indicate the carrying amount may not be recoverable are based on company-specific inputs and our assumptions about the marketability of the properties as observable inputs are not available. As such, we have determined that these fair value measurements generally reside within Level 3 of the fair value hierarchy. We estimate the fair value of real estate deemed to not be recoverable using the cost or income approach and unobservable data such as net operating income and estimated capitalization and discount rates, and giving consideration to local and national industry market data including comparable sales.

⁽²⁾ Level 1 within fair value hierarchy.

⁽³⁾ Level 2 within fair value hierarchy.

⁽⁴⁾ Level 3 within fair value hierarchy.

⁽⁵⁾ Included in other assets on our Consolidated Balance Sheets.

⁽⁶⁾ Included in accounts payable and other liabilities on our Consolidated Balance Sheets.

NOTE 12—COMMITMENTS AND CONTINGENCIES

From time to time, we are party to various lawsuits, investigations, claims and other legal and regulatory proceedings arising in connection with our business. In certain circumstances, regardless of whether we are a named party in a lawsuit, investigation, claim or other legal or regulatory proceeding, we may be contractually obligated to indemnify, defend and hold harmless our tenants, operators, managers or other third parties against, or may otherwise be responsible for, such actions, proceedings or claims. These claims may include, among other things, professional liability and general liability claims, commercial liability claims, unfair business practices claims and employment claims, as well as regulatory proceedings and government investigations, including proceedings related to our senior housing operating portfolio, where we are typically the holder of the applicable healthcare license. These claims may not be fully insured and some may allege large damage amounts.

It is the opinion of management, that the disposition of any such lawsuits, investigations, claims and other legal and regulatory proceedings that are currently pending will not, individually or in the aggregate, have a material adverse effect on us. However, regardless of the merits of a particular action, investigation or claim, we may be forced to expend significant financial resources to defend and resolve these matters. We are unable to predict the ultimate outcome of these lawsuits, investigations, claims and other legal and regulatory proceedings, and if management's assessment of our liability with respect thereto is incorrect, such actions, investigations and claims could have a material adverse effect on us.

From time to time, on behalf of ourselves or on behalf of our unconsolidated entities, we have agreed, and may in the future agree, to provide guarantees, indemnities or other similar contingent obligations to third parties. Such agreements may include, without limitation: (1) guarantees of all or a portion of the principal, interest and other amounts due under mortgage debt or other borrowings, (2) customary nonrecourse carve-out guarantees provided in connection with mortgage or other borrowings, (3) customary indemnifications of lenders for potential environmental liabilities, (4) completion guarantees provided to lenders, tenants, ground lessors or other third parties for the completion of development and redevelopment projects, (5) guarantees of payment of contingent tax obligations to tax credit investors who have purchased historic, new market and other tax credits from us or our unconsolidated entities, (6) guarantees of ground rent and other payment of ground rent and other obligations to ground lessors and (7) indemnities and other guarantees required in connection with the procurement of performance and surety bonds and standby letters of credit.

As of June 30, 2024, it is the opinion of management that (i) our liability under these arrangements is not quantifiable and (ii) the risk of us being required to make payments under these arrangements is remote, in each case, individually and in the aggregate. Accordingly, no contingent liability is recorded in our Consolidated Balance Sheet for any of these arrangements.

NOTE 13—INCOME TAXES

We have elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code of 1986, as amended, for every year beginning with the year ended December 31, 1999. We have also elected for certain of our subsidiaries to be treated as taxable REIT subsidiaries ("TRS" or "TRS entities"), which are subject to federal, state and foreign income taxes. All entities other than the TRS entities are collectively referred to as the "REIT" within this note. Certain REIT entities are subject to foreign income tax.

Although the TRS entities and certain other foreign entities have paid minimal federal, state and foreign income taxes for the six months ended June 30, 2024, their income tax liabilities may increase in future periods as we exhaust net operating loss ("NOL") carryforwards and as our operations grow. Such increases could be significant.

Our consolidated provision for income taxes for the three months ended June 30, 2024 and 2023 was an expense of \$7.8 million and a benefit of \$9.8 million, respectively. Our consolidated provision for income taxes for the six months ended June 30, 2024 and 2023 was an expense of \$4.8 million and a benefit of \$12.6 million, respectively. The income tax expense for the three and six months ended June 30, 2024 is primarily due to the enactment of Bill C-59 in Canada, which limits the amount of interest expense we can deduct with respect to our Canadian entities. Bill C-59 is retrospectively applied to October 1, 2023 and the cumulative effect tax of such interest limitation was recognized in the current quarter. The impact of the interest limitation was partially offset by reversal of valuation allowances recorded against the net deferred tax assets of certain of our TRS entities and losses in certain of our TRS entities. The income tax benefit for the three and six months ended June 30, 2023 was primarily due to losses in certain of our TRS entities as well as an \$8.0 million benefit from internal restructurings of our U.S. TRS entities.

Each TRS is a tax paying component for purposes of classifying deferred tax assets and liabilities. Deferred tax liabilities with respect to our TRS entities totaled \$32.7 million and \$24.5 million as of June 30, 2024 and December 31, 2023, respectively, and related primarily to differences between the financial reporting and tax bases of fixed and intangible assets, net of loss carryforwards. Deferred tax assets with respect to our TRS entities totaled \$1.7 million and \$1.8 million as of June 30, 2024 and December 31, 2023, respectively, and related primarily to loss carryforwards.

Generally, we are subject to audit under the statute of limitations by the Internal Revenue Service for the year ended December 31, 2020 and subsequent years and are subject to audit by state taxing authorities for the year ended December 31, 2019 and subsequent years. We are subject to audit generally under the statutes of limitation by the Canada Revenue Agency and provincial authorities with respect to the Canadian entities for the year ended December 31, 2019 and subsequent years. We are subject to audit in the United Kingdom generally for periods ended in and subsequent to 2022.

NOTE 14—STOCKHOLDERS' EQUITY

Capital Stock

We participate in an "at-the-market" equity offering program ("ATM program"), pursuant to which we may, from time to time, sell up to \$1.0 billion aggregate gross sales price of shares of our common stock. During the six months ended June 30, 2024, we sold 10.4 million shares of our common stock under our ATM program for gross proceeds of \$499.4 million, representing an average price of \$47.87 per share. As of June 30, 2024, the remaining amount available under our ATM program for future sales of common stock was \$500.6 million.

Accumulated Other Comprehensive Loss

The following is a summary of our accumulated other comprehensive loss (dollars in thousands):

	As of	June 30, 2024	As of December 31, 2023
Foreign currency translation loss	\$	(46,289)	\$ (56,596)
Unrealized loss on available for sale securities		(1,978)	(1,256)
Unrealized gain on derivative instruments		30,858	22,095
Total accumulated other comprehensive loss	\$	(17,409)	\$ (35,757)

NOTE 15—EARNINGS PER SHARE

The following table shows the amounts used in computing our basic and diluted earnings per share (in thousands, except per share amounts):

	For the Three Months Ended Jun 30,					For the Six Months Ended J		
		2024		2023		2024	2023	
Numerator for basic and diluted earnings per share:								
Income from continuing operations	\$	21,168	\$	105,066	\$	8,628	\$	123,978
Net income		21,168		105,066		8,628		123,978
Net income attributable to noncontrolling interests		1,781		1,613	_	3,553		3,008
Net income attributable to common stockholders	\$	19,387	\$	103,453	\$	5,075	\$	120,970
Denominator:						_		
Denominator for basic earnings per share—weighted average shares		408,097		400,431		405,747		400,211
Effect of dilutive securities:								
Restricted stock awards		308		220		293		268
OP unitholder interests		3,418		3,471		3,432		3,478
Denominator for diluted earnings per share—adjusted weighted average shares		411,823		404,122		409,472		403,957
Basic earnings per share:								_
Income from continuing operations	\$	0.05	\$	0.26	\$	0.02	\$	0.31
Net income attributable to common stockholders		0.05		0.26		0.01		0.30
Diluted earnings per share: (1)								
Income from continuing operations	\$	0.05	\$	0.26	\$	0.02	\$	0.31
Net income attributable to common stockholders		0.05		0.26		0.01		0.30

⁽¹⁾ Potential common shares are not included in the computation of diluted earnings per share when a loss from continuing operations exists as the effect would be an antidilutive per share amount.

The dilutive effect of our Exchangeable Notes is calculated using the if-converted method in accordance with ASU 2020-06. We are required, pursuant to the indenture governing the Exchangeable Notes, to settle the aggregate principal amount of the Exchangeable Notes in cash and may elect to settle any remaining exchange obligation (i.e., the stock price in excess of the exchange obligation) in cash, shares of our common stock, or a combination thereof. Under the if-converted method, we include the number of shares required to satisfy the exchange obligation, assuming all the Exchangeable Notes are exchanged. The average closing price of our common stock for the three and six months ended June 30, 2024 is used as the basis for determining the dilutive effect on earnings per share. The average price of our common stock for each of the three and six months ended June 30, 2024 was less than the initial exchange price of \$54.81 and, therefore, all associated shares were antidilutive.

NOTE 16—SEGMENT INFORMATION

As of June 30, 2024, we operated through three reportable business segments: SHOP, outpatient medical and research portfolio and triple-net leased properties. In our SHOP segment, we invest in senior housing communities throughout the United States and Canada and engage operators to operate those communities. In our outpatient medical and research portfolio segment, we primarily acquire, own, develop, lease and manage outpatient medical buildings and research centers throughout the United States. In our triple-net leased properties segment, we invest in and own senior housing communities, skilled nursing facilities ("SNFs"), long-term acute care facilities ("LTACs"), freestanding inpatient rehabilitation facilities ("IRFs") and other healthcare facilities throughout the United States and the United Kingdom and lease those properties to tenants under triple-net or absolute-net leases that obligate the tenants to pay all property-related expenses, including maintenance, utilities, repairs, taxes, insurance and capital expenditures. Information provided for "non-segment" includes management fees and promote revenues, net of expenses related to our third-party institutional capital management business, income from loans and investments and various corporate-level expenses not directly attributable to any of our three reportable business segments. Non-segment assets consist primarily of corporate assets, including cash, restricted cash, loans receivable and investments and miscellaneous accounts receivable as well as investments in unconsolidated entities including VIM.

Our chief operating decision maker evaluates performance of the combined properties in each reportable business segment and determines how to allocate resources to those segments, in significant part, based on NOI and related measures for each segment. We define NOI as total revenues, less interest and other income, property-level operating expenses and third party capital management expenses. We consider NOI useful because it allows investors, analysts and our management to measure unlevered property-level operating results and to compare our operating results to the operating results of other real estate companies between periods on a consistent basis. In order to facilitate a clear understanding of our historical consolidated operating results, NOI should be examined in conjunction with net income attributable to common stockholders as presented in our Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and reconciliations of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

Interest expense, depreciation and amortization, general, administrative and professional fees, income tax expense and other non-property-specific revenues and expenses are not allocated to individual reportable business segments for purposes of assessing segment performance. There are no intersegment sales or transfers.

Summary information by reportable business segment is as follows (dollars in thousands):

	For the Three Months Ended June 30, 2024								
		SHOP		Outpatient Medical and Research Portfolio		Triple-Net Leased Properties	No	n-Segment	Total
Revenues									
Rental income	\$	_	\$	218,853	\$	153,934	\$	_	\$ 372,787
Resident fees and services		817,600		_		_		_	817,600
Third party capital management revenues		_		706		_		3,626	4,332
Income from loans and investments		_		_		_		1,436	1,436
Interest and other income				_				4,825	4,825
Total revenues	\$	817,600	\$	219,559	\$	153,934	\$	9,887	\$ 1,200,980
Total revenues	\$	817,600	\$	219,559	\$	153,934	\$	9,887	\$ 1,200,980
Less:									
Interest and other income		_		_		_		4,825	4,825
Property-level operating expenses		603,359		73,286		3,506		_	680,151
Third party capital management expenses		_		_		_		1,650	1,650
NOI	\$	214,241	\$	146,273	\$	150,428	\$	3,412	514,354
Interest and other income									4,825
Interest expense									(149,259)
Depreciation and amortization									(339,848)
General, administrative and professional fees									(37,727)
Loss on extinguishment of debt, net									(420)
Transaction, transition and restructuring costs									(2,886)
Allowance on loans receivable and investments, net									42
Shareholder relations matters									(37)
Other expense									(8,128)
Loss from unconsolidated entities									(1,652)
Gain on real estate dispositions									49,670
Income tax expense									(7,766)
Income from continuing operations									 21,168
Net income									21,168
Net income attributable to noncontrolling interests									1,781
Net income attributable to common stockholders									\$ 19,387

	For the Three Months Ended June 30, 2023									
		SHOP		Outpatient Medical and Research Portfolio		Triple-Net Leased Properties	No	on-Segment		Total
Revenues										
Rental income	\$	_	\$	215,807	\$	154,355	\$	_	\$	370,162
Resident fees and services		724,614		_		_		_		724,614
Third party capital management revenues		_		559				3,437		3,996
Income from loans and investments		_		_		_		6,554		6,554
Interest and other income								1,032		1,032
Total revenues	\$	724,614	\$	216,366	\$	154,355	\$	11,023	\$	1,106,358
Total revenues	\$	724,614	\$	216,366	\$	154,355	\$	11,023	\$	1,106,358
Less:										
Interest and other income		_		_		_		1,032		1,032
Property-level operating expenses		547,110		72,171		3,537		_		622,818
Third party capital management expenses		_		_		_		1,436		1,436
NOI	\$	177,504	\$	144,195	\$	150,818	\$	8,555		481,072
Interest and other income										1,032
Interest expense										(143,265)
Depreciation and amortization										(304,689)
General, administrative and professional fees										(34,399)
Gain on extinguishment of debt, net										6,801
Transaction, transition and restructuring costs										(3,069)
Allowance on loans receivable and investments, net										12,065
Gain on foreclosure of real estate										29,127
Other income										17,959
Income from unconsolidated entities										31,254
Gain on real estate dispositions										1,405
Income tax benefit										9,773
Income from continuing operations										105,066
Net income										105,066
Net income attributable to noncontrolling interests										1,613
Net income attributable to common stockholders									\$	103,453

	For the Six Months Ended June 30, 2024									
		SHOP		Outpatient Medical and Research Portfolio		Triple-Net Leased Properties	No	on-Segment		Total
Revenues										
Rental income	\$		\$	437,730	\$	309,302	\$	_	\$	747,032
Resident fees and services		1,630,904		_		_		_		1,630,904
Third party capital management revenues				1,336				7,292		8,628
Income from loans and investments		_		_		_		2,725		2,725
Interest and other income								11,605		11,605
Total revenues	\$	1,630,904	\$	439,066	\$	309,302	\$	21,622	\$	2,400,894
Total revenues	\$	1,630,904	\$	439,066	\$	309,302	\$	21,622	\$	2,400,894
Less:										
Interest and other income		_		_		_		11,605		11,605
Property-level operating expenses		1,213,180		147,224		7,244		· —		1,367,648
Third party capital management expenses								3,403		3,403
NOI	\$	417,724	\$	291,842	\$	302,058	\$	6,614		1,018,238
Interest and other income										11,605
Interest expense										(299,192)
Depreciation and amortization										(640,103)
General, administrative and professional fees										(86,464)
Loss on extinguishment of debt, net										(672)
Transaction, transition and restructuring costs										(7,563)
Allowance on loans receivable and investments, net										110
Shareholder relations matters										(15,751)
Other expense										(6,794)
Loss from unconsolidated entities										(10,035)
Gain on real estate dispositions										50,011
Income tax expense										(4,762)
Income from continuing operations										8,628
Net income										8,628
Net income attributable to noncontrolling interests										3,553
Net income attributable to common stockholders									\$	5,075

For the Six Months Ended June 30, 2023 Outpatient Medical and **Triple-Net** Leased Research SHOP Portfolio **Properties** Non-Segment **Total** Revenues \$ 722,905 Rental income \$ 418,811 \$ 304,094 \$ Resident fees and services 1,429,607 1,429,607 6,986 Third party capital management revenues 1,187 8,173 Income from loans and investments 20,143 20,143 2,775 Interest and other income 2,775 \$ 1,429,607 304,094 29,904 \$ 419,998 \$ 2,183,603 Total revenues Total revenues \$ 1,429,607 29,904 2,183,603 419,998 304,094 Less: Interest and other income 2,775 2,775 Property-level operating expenses 1,084,332 139,084 7,333 1,230,749 3,142 Third party capital management expenses 3,142 \$ 345,275 280,914 296,761 23,987 946,937 Interest and other income 2,775 Interest expense (271,340)Depreciation and amortization (586,808) General, administrative and professional fees (79,197)Gain on extinguishment of debt, net 6,801 Transaction, transition and restructuring costs (4,455)Allowance on loans receivable and investments, net 20,129 Gain on foreclosure of real estate 29,127 Other income 10,197 Income from unconsolidated entities 25,631 Gain on real estate dispositions 11,606 12,575 Income tax benefit 123,978 Income from continuing operations Net income 123,978 Net income attributable to noncontrolling interests 3,008 120,970 Net income attributable to common stockholders

Assets by reportable business segment are as follows (dollars in thousands):

	As of June 30, 2024			As of December 31, 2023			
Assets:							
SHOP	\$ 12,944,144	52.8 %	\$	12,864,029	52.0 %		
Outpatient medical and research portfolio	6,893,756	28.1		6,943,446	28.1		
Triple-net leased properties	3,902,304	15.9		4,120,691	16.7		
Non-segment	790,025	3.2		797,267	3.2		
Total assets	\$ 24,530,229	100.0 %	\$	24,725,433	100.0 %		

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless otherwise indicated or except where the context otherwise requires, the terms "we," "us," "our," "Company" and other similar terms in Item 2 of this Quarterly Report on Form 10-Q refer to Ventas, Inc. and its consolidated subsidiaries.

Cautionary Statements

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among others, statements of expectations, beliefs, future plans and strategies, anticipated results from operations and developments and other matters that are not historical facts. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "assume," "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "opportunity," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof.

Forward-looking statements are based on management's beliefs as well as on a number of assumptions concerning future events. You should not put undue reliance on these forward-looking statements, which are not a guarantee of performance and are subject to a number of uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. We do not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made. We urge you to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance, including those made below and in our filings with the Securities and Exchange Commission, such as in the sections titled "Cautionary Statements — Summary Risk Factors," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023 and our subsequent Quarterly Reports on Form 10-Q.

Certain factors that could affect our future results and our ability to achieve our stated goals include, but are not limited to: (a) our ability to achieve the anticipated benefits and synergies from, and effectively integrate, our completed or anticipated acquisitions and investments; (b) our exposure and the exposure of our tenants, managers and borrowers to complex healthcare and other regulation, including evolving laws and regulations regarding data privacy and cybersecurity and environmental matters, and the challenges and expense associated with complying with such regulation; (c) the potential for significant general and commercial claims, legal actions, investigations, regulatory proceedings and enforcement actions that could subject us or our tenants, managers or borrowers to increased operating costs, uninsured liabilities, including fines and other penalties, reputational harm or significant operational limitations, including the loss or suspension of or moratoriums on accreditations, licenses or certificates of need, suspension of or nonpayment for new admissions, denial of reimbursement, suspension, decertification or exclusion from federal, state or foreign healthcare programs or the closure of facilities or communities; (d) the impact of market and general economic conditions on us, our tenants, managers and borrowers and in areas in which our properties are geographically concentrated, including macroeconomic trends and financial market events, such as bank failures and other events affecting financial institutions, market volatility, increases in inflation, changes in or elevated interest and exchange rates, tightening of lending standards and reduced availability of credit or capital. geopolitical conditions, supply chain pressures, rising labor costs and historically low unemployment, events that affect consumer confidence, our occupancy rates and resident fee revenues, and the actual and perceived state of the real estate markets, labor markets and public and private capital markets; (e) our reliance and the reliance of our tenants, managers and borrowers on the financial, credit and capital markets and the risk that those markets may be disrupted or become constrained; (f) the implementation and impact of regulations related to the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") and other stimulus legislation, including the risk that some or all of the CARES Act or other COVID-19 relief payments we or our tenants, managers or borrowers received could be recouped; (g) our ability, and the ability of our tenants, managers and borrowers, to navigate the trends impacting our or their businesses and the industries in which we or they operate, and the financial condition or business prospect of our tenants, managers and borrowers; (h) the risk of bankruptcy, inability to obtain benefits from governmental programs, insolvency or financial deterioration of our tenants, managers, borrowers and other obligors which may, among other things, have an adverse impact on the ability of such parties to make payments or meet their other obligations to us, which could have an adverse impact on our results of operations and financial condition; (i) the risk that the borrowers under our loans or other investments default or that, to the extent we are able to foreclose or otherwise acquire the collateral securing our loans or other investments, we will be required to incur additional expense or indebtedness in connection therewith, that the assets will underperform expectations or that we may not be able to subsequently dispose of all or part of such assets on favorable terms; (j) our current and future amount of outstanding indebtedness, and our ability to access capital

and to incur additional debt which is subject to our compliance with covenants in instruments governing our and our subsidiaries' existing indebtedness; (k) risks related to the recognition of reserves, allowances, credit losses or impairment charges which are inherently uncertain and may increase or decrease in the future and may not represent or reflect the ultimate value of, or loss that we ultimately realize with respect to, the relevant assets, which could have an adverse impact on our results of operations and financial condition; (1) the risk that our leases or management agreements are not renewed or are renewed on less favorable terms, that our tenants or managers default under those agreements or that we are unable to replace tenants or managers on a timely basis or on favorable terms, if at all; (m) our ability to identify and consummate future investments in, or dispositions of, healthcare assets and effectively manage our portfolio opportunities and our investments in co-investment vehicles, joint ventures and minority interests, including our ability to dispose of such assets on favorable terms as a result of rights of first offer or rights of first refusal in favor of third parties; (n) risks related to development, redevelopment and construction projects, including costs associated with inflation, rising or elevated interest rates, labor conditions and supply chain pressures, and risks related to increased construction and development in markets in which our properties are located, including adverse effect on our future occupancy rates; (o) our ability to attract and retain talented employees; (p) the limitations and significant requirements imposed upon our business as a result of our status as a REIT and the adverse consequences (including the possible loss of our status as a REIT) that would result if we are not able to comply with such requirements; (q) the ownership limits contained in our certificate of incorporation with respect to our capital stock in order to preserve our qualification as a REIT, which may delay, defer or prevent a change of control of our company; (r) the risk of changes in healthcare law or regulation or in tax laws, guidance and interpretations, particularly as applied to REITs, that could adversely affect us or our tenants, managers or borrowers; (s) increases in our borrowing costs as a result of becoming more leveraged, including in connection with acquisitions or other investment activity and rising or elevated interest rates; (t) our reliance on thirdparty managers and tenants to operate or exert substantial control over properties they manage for, or rent from, us, which limits our control and influence over such operations and results; (u) our exposure to various operational risks, liabilities and claims from our operating assets; (v) our dependency on a limited number of tenants and managers for a significant portion of our revenues and operating income; (w) our exposure to particular risks due to our specific asset classes and operating markets, such as adverse changes affecting our specific asset classes and the real estate industry, the competitiveness or financial viability of hospitals on or near the campuses where our outpatient medical buildings are located, our relationships with universities, the level of expense and uncertainty of our research tenants, and the limitation of our uses of some properties we own that are subject to ground lease, air rights or other restrictive agreements; (x) the risk of damage to our reputation; (y) the availability, adequacy and pricing of insurance coverage provided by our policies and policies maintained by our tenants, managers or other counterparties; (z) the risk of exposure to unknown liabilities from our investments in properties or businesses; (aa) the occurrence of cybersecurity threats and incidents that could disrupt our or our tenants', managers' or borrower's operations, result in the loss of confidential or personal information or damage our business relationships and reputation; (bb) the failure to maintain effective internal controls, which could harm our business, results of operations and financial condition; (cc) the impact of merger, acquisition and investment activity in the healthcare industry or otherwise affecting our tenants, managers or borrowers; (dd) disruptions to the management and operations of our business and the uncertainties caused by activist investors; (ee) the risk of catastrophic or extreme weather and other natural events and the physical effects of climate change; (ff) the risk of potential dilution resulting from future sales or issuances of our equity securities; and (gg) the other factors set forth in our periodic filings with the SEC.

Note Regarding Third-Party Information

This Quarterly Report includes information that has been derived from SEC filings that have been provided to us by our tenants and managers or been derived from SEC filings or other publicly available information of our tenants and managers. We believe that such information is accurate and that the sources from which it has been obtained are reliable. However, we cannot guarantee the accuracy of such information and have not independently verified the assumptions on which such information is based.

Company Overview

Ventas, Inc., an S&P 500 company, is a real estate investment trust operating at the intersection of healthcare and real estate. We hold a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. As of June 30, 2024, we owned or had investments in approximately 1,350 properties (including properties classified as held for sale and unconsolidated properties). Our company is headquartered in Chicago, Illinois with additional corporate offices in Louisville, Kentucky and New York, New York.

We elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code (the "Code"), commencing with our taxable year ended December 31, 1999. Provided we qualify for taxation as a REIT, we generally will not be required to pay U.S. federal corporate income taxes on our REIT taxable income that is currently distributed to our stockholders. In order to maintain our qualification as a REIT, we must satisfy a number of highly technical requirements, which impact how we invest in, operate or manage our assets.

We primarily invest in our portfolio of real estate assets through wholly-owned subsidiaries and other co-investment entities. We operate through three reportable business segments: senior housing operating portfolio, which we also refer to as "SHOP," outpatient medical and research portfolio, which we also refer to as "OM&R," and triple-net leased properties. Non-segment assets consist primarily of corporate assets, including cash, restricted cash, loans receivable and investments and miscellaneous accounts receivable as well as investments in unconsolidated entities. In addition, from time to time, we make secured and unsecured loans and other investments relating to real estate or operators. Our chief operating decision maker evaluates performance of the combined properties in each operating segment and determines how to allocate resources to these segments, in significant part, based on net operating income ("NOI") and related measures for each segment. See our Consolidated Financial Statements and the related notes, including "Note 16 – Segment Information," included in Item 1 of this Quarterly Report on Form 10-Q.

We also have investments in unconsolidated entities, including through our third-party institutional capital management business, Ventas Investment Management ("VIM"). Through VIM, we partner with third-party institutional investors to invest in real estate through various joint ventures and other coinvestment vehicles where we are the sponsor or general partner, including our open-ended investment vehicle, the Ventas Life Science & Healthcare Real Estate Fund (the "Ventas Fund").

The following table summarizes information for our consolidated reportable business segments and non-segment assets for the six months ended June 30, 2024 (dollars in thousands):

Segment	Total NOI (1)	Percentage of Total NOI	Number of Consolidated Properties
Senior housing operating portfolio (SHOP)	\$ 417,724	41.0 %	582
Outpatient medical and research portfolio (OM&R)	291,842	28.7 %	428
Triple-net leased properties	302,058	29.7 %	308
Non-segment (2)	6,614	0.6 %	<u> </u>
	\$ 1,018,238	100 %	1,318

^{(1) &}quot;NOI" is defined as total revenues, less interest and other income, property-level operating expenses and third party capital management expenses. See "Non-GAAP Financial Measures" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and a reconciliation of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

We enable exceptional environments that benefit a large and growing aging population. We aim to enhance shareholder value by delivering consistent superior total returns through a strategy of (1) delivering profitable organic growth in senior housing, (2) capturing value creating external growth opportunities focused on senior housing, (3) driving strong cash flow generation throughout our portfolio and (4) preserving and enhancing financial strength, flexibility and liquidity.

Our ability to access capital in a timely and cost-effective manner is critical to the success of our business strategy because it affects our ability to satisfy existing obligations, including the repayment of maturing indebtedness, and to make future investments. Factors such as general market conditions, interest rates, credit ratings on our securities, expectations of our potential future earnings and cash distributions, and the trading price of our common stock impact our access to and cost of external capital. For that reason, we generally attempt to match the long-term duration of our investments in real property with long-term financing through the issuance of shares of our common stock or the incurrence of long-term fixed rate debt.

⁽²⁾ NOI for non-segment includes management fees and promote revenues, net of expenses related to our third-party institutional capital management business, income from loans and investments and various corporate-level expenses not directly attributable to any of our three reportable business segments.

Market Trends

Our operations have historically been and are expected to continue to be impacted by economic and market conditions. We expect senior housing to benefit from strong supply/demand fundamentals, including robust projected demand growth combined with low projected supply growth. Senior housing is expected to benefit from a large and growing aging demographic in the United States, with the 80+ population anticipated to grow by more than 24% through 2029. United States senior housing construction starts are at their lowest point since 2010.

Continual improvement in the performance and growth of our business will also depend on the broader macroeconomic environment, including interest rates, inflation and GDP growth.

See "Risk Factors" in Part I, Item 1A of the 2023 Annual Report for additional discussion of risks affecting our business.

2024 Highlights

Investments and Dispositions

- During the six months ended June 30, 2024, we acquired 11 senior housing communities reported within our SHOP segment for an aggregate purchase price of \$327.4 million.
- During the six months ended June 30, 2024, we sold 15 senior housing communities, 10 outpatient medical buildings (one of which was vacant) and 23 triple-net leased properties for aggregate consideration of \$234.1 million and recognized a gain on the sale of these assets of \$50.0 million in our Consolidated Statements of Income.

Liquidity and Capital

As of June 30, 2024, we had \$3.3 billion in liquidity, including availability under our revolving credit facility and cash and cash equivalents on hand, with no borrowings outstanding under our commercial paper program.

Senior Notes

- In February 2024, Ventas Canada Finance Limited ("Ventas Canada") issued and sold \$475.3 million (C\$650.0 million) aggregate principal amount of 5.10% Senior Notes, Series J due 2029 in a private placement. The proceeds were primarily used to repay a \$367.9 million (C\$500.0 million) unsecured term loan facility due 2025.
- In April and May 2024, we repaid \$800.0 million senior notes consisting of \$400.0 million aggregate principal amount of 3.50% Senior Notes due 2024 and \$400.0 million aggregate principal amount of 3.75% Senior Notes due 2024 at maturity primarily with cash on hand and through our commercial paper program.
- In April 2024, we repaid \$53.4 million (C\$73.0 million) aggregate principal amount of 2.80% Senior Notes, Series E due 2024 at maturity with cash on hand.
- In May 2024, Ventas Realty issued and sold \$500.0 million aggregate principal amount of 5.625% Senior Notes due 2034 in a registered public offering. The proceeds were primarily used to repay balances outstanding under our commercial paper program.

Mortgages

- In February 2024, we entered into a C\$52.8 million fixed rate mortgage loan, which accrues interest at 4.644%, matures in 2029 and is secured by one senior housing community in Canada.
- In April 2024, we entered into an aggregate C\$103.0 million fixed rate mortgage loans, which accrue interest at a blended rate of 4.90%, mature in 2029 and are secured by two senior housing communities in Canada.
- In May 2024, we entered into a \$52.3 million fixed rate mortgage loan, which accrues interest at 6.02%, matures in 2034 and is secured by one outpatient medical building in California.

Equity Offerings

• During the six months ended June 30, 2024, we sold 10.4 million shares of our common stock under our ATM program for gross proceeds of \$499.4 million, representing an average price of \$47.87 per share. As of June 30, 2024, the remaining amount available under our ATM program for future sales of common stock was \$500.6 million.

Other Items

• Following Ardent's initial public offering, which was consummated in July 2024 (the "Ardent IPO"), we held an approximately 6.5% ownership interest in Ardent. In connection with the Ardent IPO, we entered into a nomination agreement with Ardent, which provides us the right (but not the obligation) to nominate one member of the Ardent Board of Directors for so long as we beneficially own 4.0% or more of the total voting power of Ardent.

Concentration Risk

We use concentration ratios to identify, understand and evaluate the potential impact of economic downturns and other adverse events that may affect our asset types, geographic locations, business models, and tenants, operators and managers. We evaluate concentration risk in terms of investment mix and operations mix. Investment mix measures the percentage of our investments that is concentrated in a specific asset type or that is operated or managed by a particular tenant, operator or manager. Operations mix measures the percentage of our operating results that is attributed to a particular tenant, operator or manager, geographic location or business model.

The following tables reflect our concentration risk as of the dates and for the periods presented:

	As of June 30, 2024	As of December 31, 2023		
Investment mix by asset type (1):				
Senior housing communities	66.4 %	65.8 %		
Outpatient medical buildings	20.5	20.4		
Research centers	5.6	5.7		
Other healthcare facilities	4.7	4.8		
Inpatient rehabilitation facilities ("IRFs") and long-term acute care facilities ("LTACs")	1.5	1.5		
Skilled nursing facilities ("SNFs")	1.3	1.7		
Secured loans receivable and investments, net		0.1		
Total	100.0 %	100.0 %		
Investment mix by tenant, operator and manager (1):				
Atria	22.6 %	23.5 %		
Lillibridge	10.3	10.2		
Sunrise	9.5	9.0		
Brookdale	7.7	7.7		
Le Groupe Maurice	6.8	7.0		
Wexford	5.3	5.4		
Ardent	5.1	5.1		
Kindred	0.8	0.8		
All other	31.9	31.3		
Total	100.0 %	100.0 %		

Ratios are based on the gross book value of consolidated real estate investments (excluding properties classified as held for sale, development properties not yet operational and land parcels) as of each reporting date.

	For the Three Months	Ended June 30,	For the Six Months Ended June 30,		
	2024	2023	2024	2023	
Operations mix by tenant and operator and business model:					
Revenues (1):					
SHOP	68.1 %	65.6 %	67.9 %	65.5 %	
Brookdale (2)	3.1	3.4	3.1	3.4	
Ardent (3)	2.8	3.0	2.8	3.0	
Kindred	2.8	3.0	2.8	3.0	
All others	23.2	25.0	23.4	25.1	
Total	100.0 %	100.0 %	100.0 %	100.0 %	
Net operating income ("NOI"):					
SHOP	41.7 %	36.9 %	41.0 %	36.5 %	
Brookdale (2)	7.2	7.8	7.3	7.9	
Ardent (3)	6.6	6.9	6.7	7.0	
Kindred	6.6	6.9	6.6	6.8	
All others	37.9	41.5	38.4	41.8	
Total	100.0 %	100.0 %	100.0 %	100.0 %	
Operations mix by geographic location (4):					
California	13.5 %	13.7 %	13.5 %	14.0 %	
New York	7.1	7.5	7.2	7.6	
Texas	6.6	6.5	6.5	6.5	
Pennsylvania	5.0	5.2	5.1	5.2	
Illinois	4.7	4.2	4.7	4.0	
All others	63.1	62.9	63.1	62.7	
Total	100.0 %	100.0 %	100.0 %	100.0 %	

⁽¹⁾ Total revenues include third party capital management revenues, revenue from loans and investments and interest and other income (including amounts related to assets classified as held for sale).

See "Non-GAAP Financial Measures" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and reconciliations of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

Triple-Net Lease Performance and Expirations

Any failure, inability or unwillingness by our tenants to satisfy their obligations under our triple-net leases could have a material adverse effect on us. Also, if our tenants are not able or willing to renew our triple-net leases upon expiration, we may be unable to reposition the applicable properties on a timely basis or on the same or better economic terms, if at all. Although our lease expirations are staggered, the non-renewal of some or all of our triple-net leases that expire in any given year could have a material adverse effect on us. During the six months ended June 30, 2024, we had no triple-net lease renewals or expirations without renewal that, in the aggregate, had a material impact on our financial condition or results of operations for that period.

Critical Accounting Policies and Estimates

Our Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information set forth in the Accounting Standards Codification ("ASC"), as published by the Financial Accounting Standards Board ("FASB"), and with the SEC instructions to Form 10-Q and Article 10 of Regulation S-X. GAAP requires us to make estimates and

⁽²⁾ Results exclude 10 senior housing communities which are included in our SHOP segment.

⁽³⁾ Results exclude 19 outpatient medical buildings which are included in our outpatient medical and research portfolio segment.

⁽⁴⁾ Ratios are based on total revenues (including amounts related to assets classified as held for sale) for each period presented.

assumptions regarding future events that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions and, in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain.

Our 2023 Annual Report contains additional information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes to these policies in 2024.

Recent Accounting Standards

In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which requires incremental disclosures related to a public entity's reportable segments. Required disclosures include, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount for other segment items (which is the difference between segment revenue less segment expenses and less segment profit or loss) and a description of its composition, the title and position of the CODM, and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The standard also permits disclosure of more than one measure of segment profit. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are evaluating the impact of adopting ASU 2023-07 and expect to have additional disclosures in our Form 10-K for the year ended December 31, 2024.

In December 2023, the FASB issued Accounting Standards Update 2023-09, *Improvements to Income Tax Disclosures* ("ASU 2023-09"), which requires public entities on an annual basis to (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. We are evaluating the impact of adopting ASU 2023-09 on our Consolidated Financial Statements.

In March 2024, the SEC adopted the final rule under SEC Release No. 33-11275, *The Enhancement and Standardization of Climate Related Disclosures for Investors*, which requires registrants to disclose climate-related information in registration statements and annual reports. The new rules would be effective for annual reporting periods beginning in fiscal year 2025. However, in April 2024, the SEC exercised its discretion to stay these rules pending the completion of judicial review of certain consolidated petitions with the United States Court of Appeals for the Eighth Circuit in connection with these rules. We are evaluating the impact of this rule on our Consolidated Financial Statements.

Results of Operations

As of June 30, 2024, we operated through three reportable business segments: senior housing operating portfolio, outpatient medical and research portfolio and triple-net leased properties. In our SHOP segment, we invest in senior housing communities throughout the United States and Canada and engage operators to operate those communities. In our outpatient medical and research portfolio segment, we primarily acquire, own, develop, lease and manage outpatient medical buildings and research centers throughout the United States. In our triple-net leased properties segment, we invest in and own senior housing communities, skilled nursing facilities ("SNFs"), long-term acute care facilities ("LTACs"), freestanding inpatient rehabilitation facilities ("IRFs") and other healthcare facilities throughout the United States and the United Kingdom and lease those properties to tenants under triple-net or absolute-net leases that obligate the tenants to pay all property-related expenses, including maintenance, utilities, repairs, taxes, insurance and capital expenditures. Information provided for "non-segment" includes income from loans and investments and other miscellaneous income and various corporate-level expenses not directly attributable to any of our three reportable business segments. Non-segment assets consist primarily of corporate assets, including cash, restricted cash, loans receivable and investments and miscellaneous accounts receivable as well as investments in unconsolidated entities including VIM.

Our chief operating decision maker evaluates performance of the combined properties in each reportable business segment and determines how to allocate resources to those segments, in significant part, based on NOI and related measures for

each segment. For further information regarding our reportable business segments and a discussion of our definition of NOI, see "Note 16 – Segment Information" of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. See "Non-GAAP Financial Measures" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure and reconciliations of net income attributable to common stockholders, as computed in accordance with GAAP, to NOI.

Three Months Ended June 30, 2024 and 2023

The table below shows our results of operations for the three months ended June 30, 2024 and 2023 and the effect of changes in those results from period to period on our net income attributable to common stockholders (dollars in thousands):

	For the Three Months Ended June 30,				Increase (Decrease) to Net Income		
		2024		2023	\$	%	
NOI:							
SHOP	\$	214,241	\$	177,504	\$ 36,737	20.7 %	
Outpatient medical and research portfolio		146,273		144,195	2,078	1.4	
Triple-net leased properties		150,428		150,818	(390)	(0.3)	
Non-segment		3,412		8,555	(5,143)	(60.1)	
Total NOI		514,354		481,072	 33,282	6.9	
Interest and other income		4,825		1,032	3,793	nm	
Interest expense		(149,259)		(143,265)	(5,994)	(4.2)	
Depreciation and amortization		(339,848)		(304,689)	(35,159)	(11.5)	
General, administrative and professional fees		(37,727)		(34,399)	(3,328)	(9.7)	
(Loss) gain on extinguishment of debt, net		(420)		6,801	(7,221)	(106.2)	
Transaction, transition and restructuring costs		(2,886)		(3,069)	183	6.0	
Allowance on loans receivable and investments, net		42		12,065	(12,023)	(99.7)	
Shareholder relations matters		(37)			(37)	nm	
Gain on foreclosure of real estate		_		29,127	(29,127)	100.0	
Other (expense) income		(8,128)		17,959	(26,087)	(145.3)	
(Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests		(19,084)		62,634	(81,718)	(130.5)	
(Loss) income from unconsolidated entities		(1,652)		31,254	(32,906)	(105.3)	
Gain on real estate dispositions		49,670		1,405	48,265	nm	
Income tax (expense) benefit		(7,766)		9,773	(17,539)	(179.5)	
Income from continuing operations		21,168		105,066	(83,898)	(79.9)	
Net income		21,168		105,066	(83,898)	(79.9)	
Net income attributable to noncontrolling interests		1,781		1,613	168	10.4	
Net income attributable to common stockholders	\$	19,387	\$	103,453	\$ (84,066)	(81.3)	

nm - not meaningful

NOI-SHOP

The following table summarizes results of operations in our SHOP segment, including assets sold or classified as held for sale as of June 30, 2024 (dollars in thousands):

	For the Three Months Ended June 30,					Increase (Decrease) to NOI			
		2024 202		2023 \$		\$	%		
NOI—SHOP:									
Resident fees and services	\$	817,600	\$	724,614	\$	92,986	12.8 %		
Less: Property-level operating expenses		(603,359)		(547,110)		(56,249)	(10.3)		
NOI	\$	214,241	\$	177,504	\$	36,737	20.7		
	Average	Unit Occupa	ncy fo	or the Three	Occi	Average Monthly upied Room for t	Revenue Per the Three Months		

Number of Properties at June 30,Average Unit Occupancy for the Three Occupied Room for the Three Months Ended June 30,202420232024202320242023Total communities58257083.8 %80.5 %\$ 4,893\$ 4,679

Resident fees and services include all amounts earned from residents at our senior housing communities, such as rental fees related to resident leases, extended health care fees and other ancillary service income. Property-level operating expenses related to our SHOP segment include labor, food, utilities, marketing, management and other costs of operating the properties. For senior housing communities in our SHOP segment, occupancy generally reflects average operator-reported unit occupancy for the reporting period. Average monthly revenue per occupied room reflects average resident fees and services per operator-reported occupied unit for the reporting period.

The NOI increase in our SHOP segment for the three months ended June 30, 2024 compared to the same period in 2023 was primarily driven by positive trends in occupancy and revenue per occupied room in 2024, the addition of communities acquired in our SHOP segment and conversions from our triple-net leased properties to our SHOP segment. The revenue increase is partially offset by higher operating expenses, driven by the additions to our SHOP segment and an increase in occupancy in our same-store portfolio.

The following table compares results of operations for our 477 same-store SHOP communities (dollars in thousands). See "Non-GAAP Financial Measures—NOI" included elsewhere in this Quarterly Report on Form 10-Q for additional disclosure regarding same-store NOI for each of our reportable business segments.

	For the Three Months Ended June 30,					Increase (Decrease) to NOI			
		2024		2023		\$	%		
Same-Store NOI—SHOP:									
Resident fees and services	\$	691,612	\$	640,445	\$	51,167	8.0 %		
Less: Property-level operating expenses		(502,009)		(475,837)		(26,172)	(5.5)		
NOI	\$	189,603	\$	164,608	\$	24,995	15.2		
	<u></u>				-				

	Number of Propert	ties at June 30,	Average Unit Occupan Months Ended		Average Monthly Revenue Per Occupied Room for the Three Month Ended June 30,				
	2024	2023	2024	2023	2024	2023			
Same-store communities	477	477	85.6 %	82.4 %	\$ 4,920	\$ 4,734			

The NOI increase in our same-store SHOP segment for the three months ended June 30, 2024 compared to the same period in 2023 was primarily driven by positive trends in occupancy and revenue per occupied room in 2024, partially offset by higher operating expenses driven by an increase in occupancy in 2024.

NOI—Outpatient Medical and Research Portfolio

The following table summarizes results of operations in our outpatient medical and research portfolio segment, including assets sold or classified as held for sale as of June 30, 2024 (dollars in thousands). For properties in our outpatient medical and research portfolio segment, occupancy generally reflects occupied square footage divided by net rentable square footage as of the end of the reporting period.

For the Three Months Ended June 30,				ase) to NOI		
	2024		2023		\$	%
\$	218,853	\$	215,807	\$	3,046	1.4 %
	706		559		147	26.3
	219,559		216,366		3,193	1.5
	(73,286)		(72,171)		(1,115)	(1.5)
\$	146,273	\$	144,195	\$	2,078	1.4
	\$ \$	\$ 218,853 706 219,559 (73,286)	\$ 218,853 \$ 706 219,559 (73,286)	\$ 218,853 \$ 215,807	\$ 218,853 \$ 215,807 \$ 706 559 216,366 (73,286) (72,171)	30, Increase (Decrease) 2024 2023 \$ 218,853 \$ 215,807 \$ 706 559 219,559 216,366 3,193 (73,286) (72,171) (1,115)

	Number of Pi	Annualized Occupion for the Thi	ed So	quare F	Foot			
	June 30,		Occupancy a	June 30				
	2024	2023	2024	2023	2024		2	023
Total outpatient medical and research portfolio	428	442	87.9 %	88.1 %	\$ 3	37	\$	36

The NOI increase in our outpatient medical and research portfolio segment for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to properties acquired, leasing activity and improved parking revenues, partially offset by asset dispositions.

The following table compares results of operations for our 337 same-store outpatient medical and research portfolio (dollars in thousands):

	For the Three Months Ended June 30,					Increase (Decrease) to NOI			
	2024		2023		\$		%		
Same-Store NOI—Outpatient Medical and Research Portfolio:									
Rental income	\$	187,321	\$	180,972	\$	6,349	3.5 %		
Less: Property-level operating expenses		(59,473)		(56,736)		(2,737)	(4.8)		
NOI	\$	127,848	\$	124,236	\$	3,612	2.9		

	Number of Pr June 3	- I	Occupancy at	Oc	e Rent Per re Foot ths Ended			
	2024	2023	2024	2023	202	24		2023
Same-store outpatient medical and research portfolio	337	337	91.0 %	91.1 %	\$	38	\$	36

The NOI increase in our same-store outpatient medical and research portfolio segment for the three months ended June 30, 2024 compared to the same period in 2023 was primarily driven by leasing activity, high tenant retention and improved parking revenues, partially offset by higher operating expenses.

NOI—Triple-Net Leased Properties

The following table summarizes results of operations in our 308 triple-net leased properties segment, including assets sold or classified as held for sale as of June 30, 2024 (dollars in thousands):

For the Three Months Ended June 30,					(Decrease) Increase to NOI			
	2024		2023		\$	%		
\$	153,934	\$	154,355	\$	(421)	(0.3)%		
	(3,506)		(3,537)		31	0.9		
\$	150,428	\$	150,818	\$	(390)	(0.3)		
	\$ \$	\$ 153,934 (3,506)	\$ 153,934 \$ (3,506)	\$\frac{30,}{2024} \frac{2023}{2023}\$ \$\frac{153,934}{(3,506)} \frac{154,355}{(3,537)}\$	\$ 153,934 \$ 154,355 \$ (3,506) (3,537)	\$\frac{30,}{2024} \frac{2023}{\$\sigma}\$\$ \$\frac{153,934}{(3,506)} \frac{154,355}{(3,537)} \frac{(421)}{31}\$		

In our triple-net leased properties segment, our revenues generally consist of fixed rental amounts (subject to contractual escalations) received from our tenants in accordance with the applicable lease terms. We report revenues and property-level operating expenses within our triple-net leased properties segment for real estate tax and insurance expenses that are paid from escrows collected from our tenants.

The NOI decrease in our triple-net leased properties for the three months ended June 30, 2024 compared to the same period in 2023 was primarily driven by communities that converted to our SHOP segment and dispositions, partially offset by acquisitions and contractual rent escalators in 2024.

Occupancy rates may affect the profitability of our tenants' operations. For senior housing communities and post-acute properties in our triple-net leased properties segment, occupancy generally reflects average operator-reported unit and bed occupancy, respectively, for the reporting period. Because triple-net financials are delivered to us following the reporting period, occupancy is reported in arrears. The following table sets forth average continuing occupancy rates for the first quarter of 2024 and 2023 related to the triple-net leased properties we owned at June 30, 2024 and 2023, respectively. The table excludes non-stabilized properties, properties owned through investments in unconsolidated real estate entities, certain properties for which we do not receive occupancy information and properties acquired or properties that transitioned operators for which we do not have a full quarter of occupancy results.

	Number of Properties Owned at June 30, 2024	Average Occupancy for the Three Months Ended March 31, 2024	Number of Properties Owned at June 30, 2023	Average Occupancy for the Three Months Ended March 31, 2023
Senior housing communities	215	78.0%	240	77.1%
SNFs	26	85.2	16	84.1
IRFs and LTACs	39	55.1	36	57.3

The following table compares results of operations for our 266 same-store triple-net leased properties (dollars in thousands):

	For	the Three Mo		Ended June	Increase (De	crease) to NOI
	2024			2023	\$	%
Same-Store NOI—Triple-Net Leased Properties:				_		
Rental income	\$	143,395	\$	140,183	\$ 3,212	2.3 %
Less: Property-level operating expenses		(3,141)		(2,931)	(210)	(7.2)
NOI	\$	140,254	\$	137,252	\$ 3,002	2.2

The NOI increase in our same-store triple-net leased portfolio for the three months ended June 30, 2024 compared to the same period in 2023 was primarily driven by contractual rent escalators in 2024.

NOI-Non-Segment

Non-segment NOI includes management fees and promote revenues, net of expenses, related to our third-party institutional capital management business, income from loans and investments and various corporate-level expenses not directly attributable to any of our three reportable business segments. The \$5.1 million decrease in non-segment NOI for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to the conversion of the outstanding principal amount of a loan to equity in May 2023.

Company Results

Interest and other income

The \$3.8 million increase in interest and other income for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to interest income earned on cash invested in short-term money market funds.

Interest expense

The \$6.0 million increase in interest expense, net of capitalized interest, for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to an increase of \$8.3 million due to higher effective interest rates. Our weighted average effective interest rate was 4.43% and 4.18% for the three months ended June 30, 2024 and 2023, respectively. Capitalized interest was \$3.9 million and \$2.9 million for the three months ended June 30, 2024 and 2023, respectively.

Depreciation and amortization

The \$35.2 million increase in depreciation and amortization expense for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to a \$32.3 million increase in impairments recognized in 2024 primarily related to properties that were classified as held for sale or sold and a \$6.7 million increase in depreciation and amortization related to our ownership of additional properties, partially offset by a decrease in depreciation and amortization related to properties sold after June 30, 2023.

General, administrative and professional fees

The \$3.3 million increase in general, administrative and professional fees for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to lower turnover, increased staffing and inflationary increases.

(Loss) gain on extinguishment of debt, net

The \$7.2 million change in (loss) gain on extinguishment of debt, net for the three months ended June 30, 2024 was primarily due to \$8.3 million of gain recognized in 2023 in connection with the repurchase of outstanding indebtedness in 2023 as a result of cash tender offers.

Transaction, transition and restructuring costs

Transaction, transition and restructuring costs include transition and integration expenses incurred by properties that have undergone operator or business model transitions; costs and expenses relating to mergers, acquisitions, investments, leases, management agreements and similar arrangements, strategic transactions, such as spin-offs, joint ventures, partnerships and minority investments, and other transactions; and costs and expenses related to organizational or other restructuring activities. Transaction, transition and restructuring costs for the three months ended June 30, 2024 compared to the same period in 2023 was relatively consistent.

Allowance on loans receivable and investments, net and Gain on foreclosure of real estate

In the second quarter of 2023, in connection with the Company's equitization of a mezzanine loan, the Company recognized \$41.1 million in income composed of the derecognition and reversal of a previously recorded allowance and a gain on foreclosure of real estate. These items did not recur in 2024 resulting in \$41.1 million less in income compared to the three months ended June 30, 2023 (on the allowance on loans receivable and investments, net and gain on foreclosure of real estate lines).

Other (expense) income

Other (expense) income includes the changes in fair value of stock warrants, net expenses or recoveries related to significant disruptive events and other expenses or income. The \$26.1 million change in other (expense) income for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to a \$16.2 million change in the fair value of the remaining Brookdale stock warrants received in connection with the Brookdale Senior Living lease modification in the third quarter of 2020 and a \$10.0 million decrease in insurance reimbursements received, net of impairments recognized, for damages caused by significant disruptive events. During the three months ended June 30, 2024, we exercised warrants for 1.7 million shares of Brookdale Senior Living, Inc. common stock ("Brookdale Common Stock") on a cashless basis, resulting in our receipt of 0.9 million shares of Brookdale Common Stock (net of the \$3.00 exercise price), which we sold for net cash proceeds of \$6.1 million (recorded within operating cashflows in our Consolidated Statements of Cash Flows). We recognized a \$1.0 million net realized loss relative to the fair market value of the warrants as of March 31, 2024 (recorded in Other Expense in our Consolidated Statements of Income). As of June 30, 2024, we continued to hold 14.6 million warrants for Brookdale Common Stock, which are exercisable at any time prior to December 31, 2025 and have an exercise price of \$3.00 per share. For the three months ended June 30, 2024 and 2023, we recognized unrealized loss of \$0.3 million and unrealized gain of \$15.9 million, respectively, relating to the change in fair value of the Brookdale stock warrants. As of June 30, 2024, the fair value of the remaining stock warrants was \$61.1 million, which was \$33.0 million higher than the value at the grant date.

(Loss) income from unconsolidated entities

The \$32.9 million change in (loss) income from unconsolidated entities for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to a \$33.5 million gain recognized upon the sale of approximately 24% of our 9.8% ownership interest in Ardent to a third-party investor in May 2023.

Gain on real estate dispositions

The \$48.3 million increase in gain on real estate dispositions for the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to a net gain of \$49.7 million recognized on the sale of 32 properties in 2024, partially offset by a net gain of \$1.4 million recognized in 2023 on the sale of four properties.

Income tax (expense) benefit

The \$7.8 million income tax expense for the three months ended June 30, 2024 is primarily due to the enactment of Bill C-59 in Canada, which limits the amount of interest expense we can deduct with respect to our Canadian entities. Bill C-59 is retrospectively applied to October 1, 2023 and the cumulative effect tax of such interest limitation was recognized in the current quarter. The impact of the interest limitation was partially offset by reversal of valuation allowances recorded against the net deferred tax assets of certain of our TRS entities and losses in certain of our TRS entities. The \$9.8 million income tax benefit for the three months ended June 30, 2023 was primarily due to losses in certain of our TRS entities as well as an \$8.0 million benefit from internal restructurings of our U.S. TRS entities.

Six Months Ended June 30, 2024 and 2023

The table below shows our results of operations for the six months ended June 30, 2024 and 2023 and the effect of changes in those results from period to period on our net income attributable to common stockholders (dollars in thousands):

	For	the Six Mont	hs En	ded June 30,	Increase (I to Net II	
		2024		2023	\$	%
NOI:						
SHOP	\$	417,724	\$	345,275	\$ 72,449	21.0 %
Outpatient medical and research portfolio		291,842		280,914	10,928	3.9
Triple-net leased properties		302,058		296,761	5,297	1.8
Non-segment		6,614		23,987	 (17,373)	(72.4)
Total NOI		1,018,238		946,937	 71,301	7.5
Interest and other income		11,605		2,775	8,830	nm
Interest expense		(299,192)		(271,340)	(27,852)	(10.3)
Depreciation and amortization		(640,103)		(586,808)	(53,295)	(9.1)
General, administrative and professional fees		(86,464)		(79,197)	(7,267)	(9.2)
(Loss) gain on extinguishment of debt, net		(672)		6,801	(7,473)	(109.9)
Transaction, transition and restructuring costs		(7,563)		(4,455)	(3,108)	(69.8)
Allowance on loans receivable and investments, net		110		20,129	(20,019)	(99.5)
Shareholder relations matters		(15,751)		_	(15,751)	nm
Gain on foreclosure of real estate		_		29,127	(29,127)	100.0
Other (expense) income		(6,794)		10,197	(16,991)	(166.6)
(Loss) income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests		(26,586)		74,166	(100,752)	(135.8)
(Loss) income from unconsolidated entities		(10,035)		25,631	(35,666)	(139.2)
Gain on real estate dispositions		50,011		11,606	38,405	nm
Income tax (expense) benefit		(4,762)		12,575	(17,337)	(137.9)
Income from continuing operations		8,628		123,978	(115,350)	(93.0)
Net income		8,628		123,978	(115,350)	(93.0)
Net income attributable to noncontrolling interests		3,553		3,008	(545)	(18.1)
Net income attributable to common stockholders	\$	5,075	\$	120,970	\$ (115,895)	(95.8)

nm - not meaningful

NOI—Senior Housing Operating Portfolio

The following table summarizes results of operations in our SHOP segment, including assets sold or classified as held for sale as of June 30, 2024 (dollars in thousands):

		For the Six Months Ended June 30,							Increase (Decrease) to NO			
			2024			2023		\$		%		
NOI—SHOP:												
Resident fees and services			\$	1,630,904	\$	1,429,607	\$	201,297		14.1 %		
Less: Property-level operating expenses				(1,213,180)		(1,084,332)		(128,848)		(11.9)		
NOI			\$	417,724	\$	345,275	\$	72,449		21.0		
	Number of Proper	ties at June 30,	A	verage Unit Oc Months E	cup:	ancy For the Six I June 30,		Average Mont Occupied Ro Months En	om Fo	or the Six		
	2024	2023		2024		2023		2024		2023		
Total communities	582	570		83.3 %	ó	80.6	6 \$	4,914	\$	4,653		

The NOI increase in our SHOP segment for the six months ended June 30, 2024 compared to the same period in 2023 was primarily driven by positive trends in revenue per occupied room and occupancy, conversions from our triple-net leased properties to our SHOP segment and the addition of communities acquired in our SHOP segment. The revenue increase is partially offset by higher operating expenses in 2024, driven by the additions to our SHOP segment and an increase in occupancy in our same-store portfolio.

The following table compares results of operations for our 476 same-store SHOP communities (dollars in thousands):

	Fo	r the Six Mont	hs Eı	nded June 30,		Increase (Deci	crease) to NOI		
		2024 203		2023		\$	%		
Same-Store NOI—SHOP:									
Resident fees and services	\$	1,374,951	\$	1,274,009	\$	100,942	7.9 %		
Less: Property-level operating expenses		(1,003,366)		(952,079)		(51,287)	(5.4)		
NOI	\$	371,585	\$	321,930	\$	49,655	15.4		

	Number of Propert	ies at June 30,	Average Unit Occupar Months Ended	or th	y Revenue Per r the Six Months me 30,		
	2024	2023	2024	2023	2024		2023
Same-store communities	476	476	85.2 %	82.3 %	\$ 4,926	\$	4,722

The NOI increase in our same-store SHOP segment for the six months ended June 30, 2024 compared to the same period in 2023 was primarily driven by positive trends in occupancy and revenue per occupied room in 2024, partially offset by higher operating expenses driven by an increase in occupancy in 2024.

NOI—Outpatient Medical and Research Portfolio

The following table summarizes results of operations in our outpatient medical and research portfolio segment, including assets sold or classified as held for sale as of June 30, 2024 (dollars in thousands):

	For	the Six Mont	hs Er	ided June 30,	 Increase (Decrease) to NOI			
		2024	2023		\$	%		
NOI—Outpatient Medical and Research Portfolio:	-							
Rental income	\$	437,730	\$	418,811	\$ 18,919	4.5 %		
Third party capital management revenues		1,336		1,187	149	12.6		
Total revenues		439,066		419,998	19,068	4.5		
Less:								
Property-level operating expenses		(147,224)		(139,084)	 (8,140)	(5.9)		
NOI	\$	291,842	\$	280,914	\$ 10,928	3.9		

	Number of Pr June	- I	Occupancy a	t June 30,	Occupied Squ	verage Rent Per are Foot For the Ended June 30,
	2024	2023	2024	2023	2024	2023
Total outpatient medical and research portfolio	428	442	87.9 %	88.1 %	\$ 37	\$ 36

The NOI increase in our outpatient medical and research portfolio segment for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to properties acquired, leasing activity and improved parking revenues, partially offset by dispositions and higher operating expenses.

The following table compares results of operations for our 337 same-store outpatient medical and research portfolio (dollars in thousands):

	For	the Six Mont	hs En	ded June 30,	Increase (De	crease) to NOI
		2024	24 2023		\$	%
Same-Store NOI—Outpatient Medical and Research Portfolio:						
Rental income	\$	372,987	\$	360,845	\$ 12,142	3.4 %
Less: Property-level operating expenses		(118,706)		(113,182)	(5,524)	(4.9)
NOI	\$	254,281	\$	247,663	\$ 6,618	2.7

	Number of Pr June 3	- I	Occupancy at	June 30,	Annualized Average Rent P Occupied Square Foot For Six Months Ended June 30					
	2024	2023	2024	2023	2024	2	2023			
Same-store outpatient medical and research portfolio	337	337	91.0 %	91.1 %	\$ 38	\$	36			

The NOI increase in our same-store outpatient medical and research portfolio segment for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to leasing activity, high tenant retention and improved parking revenues.

NOI—Triple-Net Leased Properties

The following table summarizes results of operations in our 308 triple-net leased properties segment, including assets sold or classified as held for sale as of June 30, 2024 (dollars in thousands):

	For	the Six Mont	hs En	ded June 30,		Increa	se to NOI		
		2024	2023		\$		%		
NOI—Triple-Net Leased Properties:									
Rental income	\$	309,302	\$	304,094	\$	5,208	1.7 %		
Less: Property-level operating expenses		(7,244)		(7,333)		89	1.2		
NOI	\$	302,058	\$	296,761	\$	5,297	1.8		

The NOI increase in our triple-net leased properties for the six months ended June 30, 2024 compared to the same period in 2023 was primarily driven by acquisitions and contractual rent escalators, partially offset by rental income from communities that converted to our SHOP segment and additional rental income received in 2023.

The following table compares results of operations for our 266 same-store triple-net leased properties (dollars in thousands):

	For	the Six Mont	hs En	ded June 30,	Increase (Decrease) to NOI			
		2024		2023	 \$	%		
Same-Store NOI—Triple-Net Leased Properties:								
Rental income	\$	286,375	\$	284,033	\$ 2,342	0.8 %		
Less: Property-level operating expenses		(6,619)		(6,251)	(368)	(5.9)		
NOI	\$	279,756	\$	277,782	\$ 1,974	0.7		

The NOI increase in our same-store triple-net leased properties segment for the six months ended June 30, 2024 compared to the same period in 2023 was primarily driven by contractual rent escalators, partially offset by additional rental income received in 2023.

NOI-Non-Segment

Non-segment NOI includes management fees and promote revenues, net of expenses, related to our third-party institutional capital management business, income from loans and investments and various corporate-level expenses not directly attributable to any of our three reportable business segments. The \$17.4 million decrease in non-segment NOI for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to the conversion of the outstanding principal amount of a loan to equity in May 2023.

Company Results

Interest and other income

The \$8.8 million increase in interest and other income for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to interest income earned on cash invested in short-term money market funds.

Interest expense

The \$27.9 million increase in interest expense, net of capitalized interest, for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to an increase of \$16.9 million due to higher effective interest rates and an increase of \$14.9 million due to higher debt balances. Our weighted average debt outstanding was \$13.4 billion and \$12.7 billion for the six months ended June 30, 2024 and 2023, respectively. Our weighted average effective interest rate was 4.37% and 4.11% for the six months ended June 30, 2024 and 2023, respectively. Capitalized interest for the six months ended June 30, 2024 and 2023 was \$6.6 million and \$5.6 million, respectively.

Depreciation and amortization

The \$53.3 million increase in depreciation and amortization expense for the six months ended June 30, 2024 compared to the same period in 2023 is primarily due to a \$33.0 million increase in depreciation and amortization related to our ownership of additional properties and a \$30.2 million increase in impairments recognized in 2024 primarily related to properties that were classified as held for sale or sold, partially offset by a decrease in depreciation and amortization related to properties sold after June 30, 2023.

General, administrative and professional fees

The \$7.3 million increase in general, administrative and professional fees for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to lower turnover, increased staffing and inflationary increases.

(Loss) gain on extinguishment of debt, net

The \$7.5 million change in (loss) gain on extinguishment of debt, net for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to \$8.3 million of gain recognized in 2023 in connection with the repurchase of outstanding indebtedness in 2023 as a result of cash tender offers.

Transaction, transition and restructuring costs

Transaction, transition and restructuring costs include transition and integration expenses incurred by properties that have undergone operator or business model transitions; costs and expenses relating to mergers, acquisitions, investments, leases, management agreements and similar arrangements, strategic transactions, such as spin-offs, joint ventures, partnerships and minority investments, and other transactions; and costs and expenses related to organizational or other restructuring activities. The \$3.1 million increase in transaction, transition and restructuring costs for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to integration costs for properties acquired and transition costs in connection with properties that have undergone operator or business model transitions.

Allowance on loans receivable and investments, net and Gain on foreclosure of real estate

For the six months ended June 30, 2023, in connection with the Company's equitization of a mezzanine loan, the Company recognized \$41.1 million in income composed of the derecognition and reversal of a previously recorded allowance and a gain on foreclosure of real estate. These items did not recur in 2024 resulting in \$41.1 million less in income compared to the six months ended June 30, 2023 (on the allowance on loans receivable and investments, net and gain on foreclosure of real estate lines).

Shareholder relations matters

Shareholder relations matters for the six months ended June 30, 2024 relates to proxy advisory costs related to our response to a proxy campaign associated with the Company's 2024 annual meeting. There were no such costs incurred for the six months ended June 30, 2023.

Other (expense) income

Other (expense) income includes the changes in fair value of stock warrants, net expenses or recoveries related to significant disruptive events and other expenses or income. The \$17.0 million change in other (expense) income for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to a \$7.9 million change in the fair value of the remaining stock warrants received in connection with the Brookdale Senior Living lease modification in the third quarter of 2020 and a \$8.0 million change in insurance reimbursements received, net of impairments recognized, for damages caused by significant disruptive events. For the six months ended June 30, 2024 and 2023, we recognized unrealized gains of \$9.0 million and \$16.8 million, respectively, relating to the change in fair value of the Brookdale stock warrants. As of June 30, 2024, the fair value of the stock warrants was \$61.1 million, which was \$33.0 million higher than the value at the grant date.

(Loss) income from unconsolidated entities

The \$35.7 million change in income (loss) from unconsolidated entities for the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to a \$33.5 million gain recognized upon the sale of approximately 24% of our 9.8% ownership interest in Ardent to a third-party investor in May 2023.

Gain on real estate dispositions

The \$38.4 million increase in gain on real estate dispositions was primarily due to a net gain of \$50.0 million recognized during the six months ended June 30, 2024 for the sale of 48 properties (one of which was vacant), partially offset by a net gain of \$11.6 million in 2023 for the sale of 15 properties (five of which were vacant).

Income tax (expense) benefit

The \$4.8 million of income tax expense for the six months ended June 30, 2024 is primarily due to the enactment of Bill C-59 in Canada, which limits the amount of interest expense we can deduct with respect to our Canadian entities. Bill C-59 is retrospectively applied to October 1, 2023 and the cumulative effect tax of such interest limitation was recognized in the current quarter. The impact of the interest limitation was partially offset by reversal of valuation allowances recorded against the net deferred tax assets of certain of our TRS entities and losses in certain of our TRS entities. The \$12.6 million of income tax benefit for the six months ended June 30, 2023 was primarily due to losses in certain of our TRS entities as well as an \$8.0 million benefit from internal restructurings of our U.S. TRS entities.

Non-GAAP Financial Measures

We consider certain non-GAAP financial measures to be useful supplemental measures of our operating performance. A non-GAAP financial measure is a measure of historical or future financial performance, financial position or cash flows that excludes or includes amounts that are not so excluded from or included in the most directly comparable measure calculated and presented in accordance with GAAP. Described below are the non-GAAP financial measures used by management to evaluate our operating performance and that we consider most useful to investors, together with reconciliations of these measures to the most directly comparable GAAP measures.

The non-GAAP financial measures we present in this Quarterly Report on Form 10-Q may not be comparable to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. You should not consider these measures as alternatives for, or superior to, financial measures calculated in accordance with GAAP. In order to facilitate a clear understanding of our consolidated historical operating results, you should examine these measures in conjunction with the most directly comparable GAAP measures as presented in our Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds From Operations and Normalized Funds From Operations Attributable to Common Stockholders

Historical cost accounting for real estate assets implicitly assumes that the value of real estate assets diminishes predictably over time. However, since real estate values historically have risen or fallen with market conditions, many industry investors deem presentations of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. For that reason, we consider Funds From Operations attributable to common stockholders ("FFO") and Normalized FFO to be appropriate supplemental measures of operating performance of an equity REIT. We believe that the presentation of FFO, combined with the presentation of required GAAP financial measures, has improved the understanding of operating results of REITs among the investing public and has helped make comparisons of REIT operating results more meaningful. Management generally considers FFO to be a useful measure for understanding and comparing our operating results because, by excluding gains and losses related to sales of previously depreciated operating real estate assets, impairment losses on depreciable real estate and real estate asset depreciation and amortization (which can differ across owners of similar assets in similar condition based on historical cost accounting and useful life estimates), FFO can help investors compare the operating performance of a company's real estate across reporting periods and to the operating performance of other companies. We believe that Normalized FFO is useful because it allows investors, analysts and our management to compare our operating performance to the operating performance of other real estate companies across periods on a consistent basis without having to account for differences caused by non-recurring items and other non-operational events such as transactions and litigation. In some cases, we provide information about identified non-cash components of FFO and Normalized FFO because it allows investors, analysts and our management to assess the impact of those item

We use the National Association of Real Estate Investment Trusts ("Nareit") definition of FFO. Nareit defines FFO as net income attributable to common stockholders (computed in accordance with GAAP) excluding gains (or losses) from sales of real estate property, including gain (or loss) on remeasurement of equity method investments and impairment write-downs of depreciable real estate, plus real estate depreciation and amortization, and after adjustments for unconsolidated entities and noncontrolling interests. Adjustments for unconsolidated entities and noncontrolling interests will be calculated to reflect FFO on the same basis. We define Normalized FFO as Nareit FFO excluding the following income and expense items, without duplication: (a) transaction, transition and restructuring costs; (b) amortization of other intangibles; (c) the impact of expenses related to asset impairment and valuation allowances; (d) the write-off of unamortized deferred financing fees or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of our debt; (e) the non-cash impact of income tax benefits or expenses; (f) the non-cash impact of changes to our executive equity compensation plan; (g) non-cash charges related to leases; (h) the financial impact of contingent consideration; (i) gains and losses on derivatives and changes in the fair value of financial instruments; (j) gains and losses on non-real estate dispositions and other normalizing items related to noncontrolling interests and unconsolidated entities; (k) net expenses or recoveries related to significant disruptive events; and (l) other items set forth in the Normalized FFO reconciliation included herein.

The following table summarizes our FFO and Normalized FFO for the three and six months ended June 30, 2024 and 2023 (dollars in thousands). Normalized FFO for the six months ended June 30, 2024 increased over the same period in 2023 due to increased net operating income from our properties led by our SHOP reportable business segment as a result of increased revenues driven by positive trends in occupancy and revenue per occupied room, partially offset by higher interest expense.

	For the Three Months Ended June 30,					For the Six Months Ended J 30,			
		2024		2023		2024		2023	
Net income attributable to common stockholders	\$	19,387	\$	103,453	\$	5,075	\$	120,970	
Adjustments:									
Depreciation and amortization on real estate assets		339,186		304,095		638,800		585,572	
Depreciation on real estate assets related to noncontrolling interests		(3,723)		(4,344)		(7,594)		(8,721)	
Depreciation on real estate assets related to unconsolidated entities		12,012		10,675		23,817		20,852	
Gain on real estate dispositions		(49,670)		(1,405)		(50,011)		(11,606)	
Gain (loss) on real estate dispositions related to noncontrolling interests		_		_		9		(5)	
Gain on real estate dispositions related to unconsolidated entities								(180)	
Nareit FFO attributable to common stockholders		317,192		412,474		610,096		706,882	
Adjustments:									
Loss (gain) on derivatives, net		1,387		(12,634)		(7,953)		(13,218)	
Non-cash income tax expense (benefit)		6,074		(11,514)		1,379		(15,813)	
Loss (gain) on extinguishment of debt, net		420		(6,801)		672		(6,801)	
Transaction, transition and restructuring costs		2,886		3,069		7,563		4,455	
Amortization of other intangibles		96		96		193		193	
Non-cash impact of changes to equity plan		(2,366)		(2,402)		5,195		4,820	
Significant disruptive events, net		2,363		(6,675)		3,522		(2,567)	
Allowance on loans receivable and investments, net		(42)		(12,065)		(110)		(20,129)	
Gain on foreclosure of real estate		_		(29,127)		_		(29,127)	
Shareholder relations matters		37		_		15,751			
Other normalizing items (1)		302		_		2,660		—	
Normalizing items related to noncontrolling interests and unconsolidated entities, net		770		(32,076)		6,726		(29,479)	
Normalized FFO attributable to common stockholders	\$	329,119	\$	302,345	\$	645,694	\$	599,216	

⁽¹⁾ Includes adjustments for unusual items, including \$0.3 million and \$2.7 million for the three and six months ended June 30, 2024, respectively, primarily related to the settlement by one of our operators of class action litigation in our SHOP segment.

NOI

We also consider NOI an important supplemental measure because it allows investors, analysts and our management to assess our unlevered property-level operating results and to compare our operating results with those of other real estate companies and between periods on a consistent basis. We define NOI as total revenues, less interest and other income, property-level operating expenses and third party capital management expenses.

The following table sets forth a reconciliation of net income attributable to common stockholders to NOI (dollars in thousands):

	For the Three Months Ended June 30,			For the Six Months Ended June 30,				
		2024 2023		2023	2024		2023	
Net income attributable to common stockholders	\$	19,387	\$	103,453	\$	5,075	\$	120,970
Adjustments:								
Interest and other income		(4,825)		(1,032)		(11,605)		(2,775)
Interest expense		149,259		143,265		299,192		271,340
Depreciation and amortization		339,848		304,689		640,103		586,808
General, administrative and professional fees		37,727		34,399		86,464		79,197
Loss (gain) on extinguishment of debt, net		420		(6,801)		672		(6,801)
Transaction, transition and restructuring costs		2,886		3,069		7,563		4,455
Allowance on loans receivable and investments, net		(42)		(12,065)		(110)		(20,129)
Gain on foreclosure of real estate		_		(29,127)		_		(29,127)
Shareholder relations matters		37		_		15,751		_
Other expense (income)		8,128		(17,959)		6,794		(10,197)
Net income attributable to noncontrolling interests		1,781		1,613		3,553		3,008
Loss (income) from unconsolidated entities		1,652		(31,254)		10,035		(25,631)
Gain on real estate dispositions		(49,670)		(1,405)		(50,011)		(11,606)
Income tax expense (benefit)		7,766		(9,773)		4,762		(12,575)
NOI	\$	514,354	\$	481,072	\$	1,018,238	\$	946,937

See "Results of Operations" for discussions regarding both NOI and same-store NOI. We define same-store as properties owned, consolidated and operational for the full period in both comparison periods and that are not otherwise excluded; provided, however, that we may include selected properties that otherwise meet the same-store criteria if they are included in substantially all of, but not a full, period for one or both of the comparison periods, and in our judgment such inclusion provides a more meaningful presentation of our segment performance.

Newly acquired development properties and recently developed or redeveloped properties in our SHOP reportable business segment will be included in same-store once they are stabilized for the full period in both periods presented. These properties are considered stabilized upon the earlier of (a) the achievement of 80% sustained occupancy or (b) 24 months from the date of acquisition or substantial completion of work. Recently developed or redeveloped properties in our outpatient medical and research portfolio and triple-net leased properties reportable business segments will be included in same-store once substantial completion of work has occurred for the full period in both periods presented. Our senior housing operating portfolio and triple-net leased properties that have undergone operator or business model transitions will be included in same-store once operating under consistent operating structures for the full period in both periods presented.

Properties are excluded from same-store if they are: (i) sold, classified as held for sale or properties whose operations were classified as discontinued operations in accordance with GAAP; (ii) impacted by significant disruptive events such as flood or fire; (iii) for SHOP, those properties that are currently undergoing a significant disruptive redevelopment; (iv) for our outpatient medical and research portfolio and triple-net leased properties reportable business segments, those properties for which management has an intention to institute, or has instituted, a redevelopment plan because the properties may require major property-level expenditures to maximize value, increase NOI, or maintain a market-competitive position and/or achieve property stabilization, most commonly as the result of an expected or actual material change in occupancy or NOI; or (v) for SHOP and triple-net leased properties reportable business segments, those properties that are scheduled to undergo operator or business model transitions, or have transitioned operators or business models after the start of the prior comparison period.

To eliminate the impact of exchange rate movements, all portfolio performance-based disclosures assume constant exchange rates across comparable periods, using the following methodology: the current period's results are shown in actual reported USD, while prior comparison period's results are adjusted and converted to USD based on the average exchange rate for the current period.

Liquidity and Capital Resources

Our principal sources of liquidity are cash flows from operations, proceeds from the issuance of debt and equity securities, borrowings under our unsecured revolving credit facility and commercial paper program, and proceeds from asset sales.

For the next 12 months, our principal liquidity needs are to: (i) fund operating expenses; (ii) meet our debt service requirements; (iii) repay maturing mortgage and other debt; (iv) fund acquisitions, investments and commitments and any development and redevelopment activities; (v) fund capital expenditures; and (vi) make distributions to our stockholders and unitholders, as required for us to continue to qualify as a REIT. Depending upon the availability of external capital, we believe our liquidity is sufficient to fund these uses of cash. We expect that these liquidity needs generally will be satisfied by a combination of the following: cash flows from operations, cash on hand, debt assumptions and financings (including secured financings), issuances of debt and equity securities, dispositions of assets (in whole or in part through joint venture arrangements with third parties) and borrowings under our revolving credit facilities and commercial paper program. However, an inability to access liquidity through multiple capital sources concurrently could have a material adverse effect on us.

Our material contractual obligations arising in the normal course of business primarily consist of long-term debt and related interest payments, and operating obligations which include ground lease obligations. During the six months ended June 30, 2024, our material contractual obligations decreased primarily due to the repayment of \$400.0 million aggregate principal amount of 3.50% Senior Notes due 2024, \$400.0 million aggregate principal amount of 3.75% Senior Notes due 2024, \$367.9 million (C\$500.0 million) unsecured term loan facility due 2025 and \$53.4 million (C\$73.0 million) aggregate principal amount of 2.80% Senior Notes, Series E due 2024, partially offset by the issuance of \$500.0 million aggregate principal amount of 5.625% Senior Notes due 2034 and \$475.3 million (C\$650.0 million) aggregate principal amount of 5.10% Senior Notes, Series J due 2029. See "Note 10 – Senior Notes Payable and Other Debt" of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information regarding our long-term debt obligations and operating obligations, respectively.

We may, from time to time, seek to retire or purchase our outstanding indebtedness for cash or in exchange for equity securities in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions, prospects for capital and other factors. The amounts involved may be material.

Credit Facilities, Commercial Paper, Unsecured Term Loans and Letters of Credit

As of June 30, 2024, we have a \$2.75 billion unsecured revolving credit facility priced at SOFR plus 0.10% applied in connection with the transition from LIBOR to SOFR ("Adjusted SOFR") plus 0.775% which is subject to adjustment based on the Company's debt ratings. Our unsecured revolving credit facility matures in April 2028, and may be extended at our option, subject to the satisfaction of certain conditions, for two additional periods of six months each. The revolving credit facility also includes an accordion feature that permits us to increase our aggregate borrowing capacity thereunder to up to \$3.75 billion, subject to the satisfaction of certain conditions, including the receipt of additional commitments for such increase.

As of June 30, 2024, we had \$2.7 billion of undrawn capacity under our unsecured revolving credit facility with \$3.2 million outstanding and an additional \$0.8 million restricted to support outstanding letters of credit. We use our unsecured revolving credit facility to support our commercial paper program and for general corporate purposes.

Our wholly-owned subsidiary, Ventas Realty, Limited Partnership ("Ventas Realty"), may issue from time to time unsecured commercial paper notes up to a maximum aggregate amount outstanding at any time of \$1.0 billion. The notes are sold under customary terms in the U.S. commercial paper note market and are ranked pari passu with all of Ventas Realty's other unsecured senior indebtedness. The notes are fully and unconditionally guaranteed by Ventas, Inc. As of June 30, 2024, we had no borrowings outstanding under our commercial paper program.

Ventas Realty has a \$500.0 million unsecured term loan priced at Adjusted SOFR plus 0.85%, which is subject to adjustment based on Ventas Realty's debt ratings. This term loan is fully and unconditionally guaranteed by Ventas, Inc. It matures in June 2027 and includes an accordion feature that permits Ventas Realty to increase the aggregate borrowings thereunder to up to \$1.25 billion, subject to the satisfaction of certain conditions, including the receipt of additional commitments for such increase.

Ventas Realty has a \$200.0 million unsecured term loan priced at Adjusted SOFR plus 0.85%, which is subject to adjustment based on Ventas Realty's debt ratings. This term loan is fully and unconditionally guaranteed by Ventas, Inc. It matures in February 2027 and includes an accordion feature that permits Ventas Realty to increase the aggregate borrowings thereunder to up to \$500.0 million, subject to the satisfaction of certain conditions, including the receipt of additional commitments for such increase.

During the six months ended June 30, 2024, we repaid and extinguished a C\$500.0 million or \$367.9 million unsecured term loan facility priced at Canadian Dollar Offered Rate ("CDOR") plus 0.90% that would otherwise have matured in January 2025. We also repaid C\$73.0 million or \$53.4 million aggregate principal amount of 2.80% Senior Notes, Series E due 2024 at maturity.

As of June 30, 2024, our \$100.0 million uncommitted line for standby letters of credit had an outstanding balance of \$14.7 million. The agreement governing the line contains certain customary covenants and, under its terms, we are required to pay a commission on each outstanding letter of credit at a fixed rate.

Exchangeable Senior Notes

In June 2023, Ventas Realty issued \$862.5 million aggregate principal amount of its 3.75% Exchangeable Senior Notes due 2026 (the "Exchangeable Notes") in a private placement. The Exchangeable Notes are senior, unsecured obligations of Ventas Realty and are fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Ventas, Inc. The Exchangeable Notes bear interest at a rate of 3.75% per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2023. The Exchangeable Notes mature on June 1, 2026, unless earlier exchanged, redeemed or repurchased. As of June 30, 2024, we had \$862.5 million aggregate principal amount of the Exchangeable Notes outstanding. During the three and six months ended June 30, 2024, we recognized approximately \$8.1 million and \$16.2 million respectively, of contractual interest expense and amortization of issuance costs of \$1.7 million and \$3.4 million, respectively, related to the Exchangeable Notes. Unamortized issuance costs of \$13.7 million as of June 30, 2024 were recorded as an offset to senior notes payable and other debt on our Consolidated Balance Sheet.

The Exchangeable Notes are exchangeable at an initial exchange rate of 18.2460 shares of our common stock per \$1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately \$54.81 per share of common stock). The initial exchange rate is subject to adjustment, including in the event of the payment of a quarterly dividend in excess of \$0.45 per share, but will not be adjusted for any accrued and unpaid interest. Upon exchange of the Exchangeable Notes, Ventas Realty will pay cash up to the aggregate principal amount of the Exchangeable Notes to be exchanged and pay or deliver (or cause to be delivered), as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at Ventas Realty's election, in respect of the remainder, if any, of its exchange obligation in excess of the aggregate principal amount of the Exchangeable Notes being exchanged. Prior to the close of business on the business day immediately preceding March 1, 2026, the Exchangeable Notes will be exchangeable at the option of the noteholders only upon the satisfaction of specified conditions and during certain periods described in the indenture governing the Exchangeable Notes. On or after March 1, 2026, until the close of business on the business day immediately preceding the maturity date, the Exchangeable Notes will be exchangeable at the option of the noteholders at any time regardless of these conditions or periods.

Senior Notes

In February 2024, Ventas Canada Finance Limited ("Ventas Canada") issued and sold \$475.3 million (C\$650.0 million) aggregate principal amount of 5.10% Senior Notes, Series J due 2029 in a private placement. The proceeds were primarily used to repay a \$367.9 million (C\$500.0 million) unsecured term loan facility due 2025.

In April and May 2024, we repaid \$800.0 million senior notes consisting of \$400.0 million aggregate principal amount of 3.50% Senior Notes due 2024 and \$400.0 million aggregate principal amount of 3.75% Senior Notes due 2024 at maturity primarily with cash on hand and through our commercial paper program.

In April 2024, we repaid \$53.4 million (C\$73.0 million) aggregate principal amount of 2.80% Senior Notes, Series E due 2024 at maturity with cash on hand.

In May 2024, Ventas Realty issued and sold \$500.0 million aggregate principal amount of 5.625% Senior Notes due 2034 in a registered public offering. The proceeds were primarily used to repay balances outstanding under our commercial paper program.

Mortgages

In February 2024, we entered into a C\$52.8 million fixed rate mortgage loan, which accrues interest at 4.644%, matures in 2029 and is secured by one senior housing community in Canada.

In April 2024, we entered into an aggregate C\$103.0 million fixed rate mortgage loans, which accrue interest at a blended rate of 4.90%, mature in 2029 and are secured by two senior housing communities in Canada.

In May 2024, we entered into a \$52.3 million fixed rate mortgage loan, which accrues interest at 6.02%, matures in 2034 and is secured by one outpatient medical building in California.

Equity Offerings

From time to time, we may sell our common stock under an "at-the-market" equity offering program ("ATM program"). During the six months ended June 30, 2024, we sold 10.4 million shares of our common stock under our ATM program for gross proceeds of \$499.4 million, representing an average price of \$47.87 per share. As of June 30, 2024, the remaining amount available under our ATM program for future sales of common stock was \$500.6 million.

Derivatives and Hedging

In the normal course of our business, interest rate fluctuations affect future cash flows under our variable rate debt obligations, loans receivable and marketable debt securities, and foreign currency exchange rate fluctuations affect our operating results. We follow established risk management policies and procedures, including the use of derivative instruments, to mitigate the impact of these risks.

We do not use derivative instruments for trading or speculative purposes, and we have a policy of entering into contracts only with major financial institutions based upon their credit ratings and other factors. When considered together with the underlying exposure that the derivative is designed to hedge, we do not expect that the use of derivatives in this manner would have any material adverse effect on our future financial condition or results of operations.

Periodically, we enter into and designate interest rate locks to partially hedge the risk of changes in interest payments attributable to increases in the benchmark interest rate during the period leading up to the probable issuance of fixed-rate debt. We designate our interest rate locks as cash flow hedges. Gains and losses when we settle our interest rate locks are amortized into earnings over the life of the related debt, except where a material amount is deemed to be ineffective, which would be immediately recognized in the Consolidated Statements of Income.

As of June 30, 2024, our variable rate debt obligations of \$0.7 billion reflect, in part, the effect of \$142.3 million notional amount of interest rate swaps with maturities in March 2027, that effectively convert fixed rate debt to variable rate debt.

As of June 30, 2024, our fixed rate debt obligations of \$12.5 billion reflect, in part, the effect of \$526.9 million and C\$643.8 million notional amount of interest rate swaps with maturities ranging from February 2025 to April 2031, in each case, that effectively convert variable rate debt to fixed rate debt.

2024 Activity

In June through August 2024, we entered into an aggregate \$200.0 million treasury locks to hedge interest rate risk on future debt issuances. The treasury locks expire in June and July 2025 and fix the 10-year U.S. treasury at 4.1%.

Dividends

During the six months ended June 30, 2024, we declared a dividend of \$0.45 per share of our common stock in each of the first and second quarter. In order to continue to qualify as a REIT, we must make annual distributions to our stockholders of at least 90% of our REIT taxable income (excluding net capital gain). In addition, we will be subject to income tax at the regular corporate rate to the extent we distribute less than 100% of our REIT taxable income, including any net capital gains. We intend to pay dividends greater than 100% of our taxable income, after the use of any net operating loss carryforwards, for 2024.

We expect that our cash flows will exceed our REIT taxable income due to depreciation and other non-cash deductions in computing REIT taxable income and that we will be able to satisfy the 90% distribution requirement. However, from time to time, we may not have sufficient cash on hand or other liquid assets to meet this requirement or we may decide to retain cash or distribute such greater amount as may be necessary to avoid income and excise taxation. If we do not have sufficient cash on hand or other liquid assets to enable us to satisfy the 90% distribution requirement, or if we desire to retain cash, we may borrow funds, issue additional equity securities, pay taxable stock dividends, if possible, distribute other property or securities or engage in a transaction intended to enable us to meet the REIT distribution requirements or any combination of the foregoing.

Cash Flows

The following table sets forth our sources and uses of cash flows for the six months ended June 30, 2024 and 2023 (dollars in thousands):

	For the Six Months Ended June 30,			Increase (Decrease) to Cash			
		2024		2023		\$	%
Cash, cash equivalents and restricted cash at beginning of period	\$	563,462	\$	170,745	\$	392,717	nm
Net cash provided by operating activities		602,320		554,644		47,676	8.6
Net cash used in investing activities		(411,387)		(127,607)		(283,780)	nm
Net cash used in financing activities		(135,427)		(388,085)		252,658	65.1
Effect of foreign currency translation		(3,684)		650		(4,334)	nm
Cash, cash equivalents and restricted cash at end of period	\$	615,284	\$	210,347	\$	404,937	192.5

nm - not meaningful

Cash Flows from Operating Activities

Cash flows from operating activities increased \$47.7 million during the six months ended June 30, 2024 compared to the same period in 2023 primarily due to higher property NOI in 2024, partially offset by higher interest expense and costs related to shareholder relations matters in 2024.

Cash Flows from Investing Activities

Net cash used in investing activities increased \$283.8 million during the six months ended June 30, 2024 compared to the same period in 2023 primarily due to higher acquisition volume and capital expenditures in 2024, partially offset by higher disposition volume in 2024.

Cash Flows from Financing Activities

Net cash used in financing activities decreased \$252.7 million during the six months ended June 30, 2024 compared to the same period in 2023 primarily due to higher issuances of common stock and a decrease in our borrowings under our commercial paper program in 2024, partially offset by lower debt issuances in 2024.

Our cash, cash equivalents and restricted cash balance as of June 30, 2024 compared to June 30, 2023 was \$404.9 million higher primarily due to proceeds raised from issuances of common stock and proceeds from sales of assets which were held in short-term investments.

Capital Expenditures

The terms of our triple-net leases generally obligate our tenants to pay all capital expenditures necessary to maintain and improve our triple-net leased properties. However, from time to time, we may fund the capital expenditures for our triple-net leased properties through loans or advances to the tenants, which may increase the amount of rent payable with respect to the properties in certain cases. We may also fund capital expenditures for which we may become responsible upon expiration of our triple-net leases or in the event that our tenants are unable or unwilling to meet their obligations under those leases. We also expect to fund capital expenditures related to our SHOP and outpatient medical and research portfolio segments with the cash flows from the properties or through additional borrowings. We expect that these liquidity needs generally will be satisfied by a combination of the following: cash flows from operations, cash on hand, debt assumptions and financings (including secured financings), issuances of debt and equity securities, dispositions of assets (in whole or in part through joint venture arrangements with third parties) and borrowings under our revolving credit facilities and commercial paper program.

To the extent that unanticipated capital expenditure needs arise or significant borrowings are required, our liquidity may be affected adversely. Our ability to borrow additional funds may be restricted in certain circumstances by the terms of the instruments governing our outstanding indebtedness.

We are party to certain agreements that obligate us to develop senior housing communities, outpatient medical buildings or research centers funded through capital that we and, in certain circumstances, our joint venture partners provide. As of June 30, 2024, we had five active and committed projects pursuant to these agreements, including three projects that are unconsolidated.

In addition, from time to time, we engage in redevelopment projects with respect to our existing senior housing communities, outpatient medical buildings and research centers to maximize the value, increase NOI, maintain a market-competitive position, achieve property stabilization or change the primary use of the property.

Off-Balance Sheet Arrangements

We own interests in certain unconsolidated entities as described in "Note 7 – Investments in Unconsolidated Entities." Except in limited circumstances, our risk of loss is limited to our investment in the joint venture and any outstanding loans receivable. In addition, we have certain properties which serve as collateral for debt that is owed by a previous owner of certain of our facilities, as described under "Note 10 – Senior Notes Payable and Other Debt" to the Consolidated Financial Statements. Our risk of loss for these certain properties is limited to the outstanding debt balance plus penalties, if any. Further, we use financial derivative instruments to hedge interest rate and foreign currency exchange rate exposure. Finally, as of June 30, 2024, we had \$15.6 million outstanding letters of credit obligations. We have no other material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources except those described above.

Guarantor and Issuer Financial Information

Ventas, Inc. has fully and unconditionally guaranteed the obligation to pay principal and interest with respect to the outstanding senior notes, including the Exchangeable Notes, issued by our 100% owned subsidiary, Ventas Realty. None of our other subsidiaries is obligated with respect to Ventas Realty's outstanding senior notes.

Ventas, Inc. has also fully and unconditionally guaranteed the obligation to pay principal and interest with respect to the outstanding senior notes issued by our 100% owned subsidiary, Ventas Canada Finance Limited ("Ventas Canada"). None of our other subsidiaries is obligated with respect to Ventas Canada's outstanding senior notes, all of which were issued on a private placement basis in Canada.

In connection with the acquisition of Nationwide Health Properties, Inc. ("NHP"), our 100% owned subsidiary Nationwide Health Properties, LLC ("NHP LLC"), as successor to NHP, assumed the obligation to pay principal and interest with respect to the outstanding senior notes issued by NHP. Neither we nor any of our subsidiaries (other than NHP LLC) is obligated with respect to any of NHP LLC's outstanding senior notes.

In addition, Ventas, Inc. has fully and unconditionally guaranteed the obligations under our \$2.75 billion unsecured revolving credit facility, our C\$500.0 million unsecured term loan facility, our \$500.0 million unsecured term loan, our \$200.0 million unsecured term loan and our \$100.0 million uncommitted line for standby letters of credit.

Under certain circumstances, contractual and legal restrictions, including those contained in the instruments governing our subsidiaries' outstanding mortgage indebtedness, may restrict our ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including our payment guarantees with respect to Ventas Realty's and Ventas Canada's senior notes.

The following summarizes our guarantor and issuer balance sheet and statement of income information as of June 30, 2024 and December 31, 2023 and for the six months ended June 30, 2024 and the year ended December 31, 2023 (in thousands) for each of Ventas Realty, as issuer of certain notes registered under the Exchange Act, and Ventas, Inc., on an unconsolidated basis, as guarantor of such notes:

Balance Sheet Information

	As of June 30, 2024			
	 Guarantor		Issuer	
Assets				
Investment in and advances to affiliates	\$ 17,838,570	\$	3,049,371	
Total assets	18,172,509		3,150,258	
Liabilities and equity				
Intercompany loans	12,777,171		(3,849,500)	
Total liabilities	13,014,558		4,575,719	
Redeemable OP unitholder and noncontrolling interests	136,554		_	
Total equity (deficit)	5,021,397		(1,425,461)	
Total liabilities and equity	18,172,509		3,150,258	

	As of December 31, 2023		
	 Guarantor	Issuer	
Assets			
Investment in and advances to affiliates	\$ 17,534,658 \$	3,049,374	
Total assets	17,845,979	3,152,334	
Liabilities and equity			
Intercompany loans	12,437,182	(4,278,847)	
Total liabilities	12,660,012	4,467,637	
Redeemable OP unitholder and noncontrolling interests	129,346	_	
Total equity (deficit)	5,056,621	(1,315,303)	
Total liabilities and equity	17,845,979	3,152,334	

Statement of Income Information

	For the Six Months Ended June 30, 2024			une 30, 2024
		Guarantor		Issuer
Equity earnings in affiliates	\$	128,792	\$	_
Total revenues		133,078		74,058
Income (loss) before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests		9,083		(113,697)
Net income (loss)		5,075		(113,697)
Net income (loss) attributable to common stockholders		5,075		(113,697)

For the V	oor Endod	December	31	2023
For the Y	ear Ended	December	.) I	. ZUZO

	Guarantor	 Issuer
Equity earnings in affiliates	\$ 31,025	\$ _
Total revenues	37,515	145,269
Loss before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests	(38,639)	(213,851)
Net loss	(40,973)	(213,851)
Net loss attributable to common stockholders	(40,973)	(213,851)

ITEM 3. OUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The following discussion of our exposure to various market risks contains forward-looking statements that involve risks and uncertainties. These projected results have been prepared utilizing certain assumptions considered reasonable in light of information currently available to us. Nevertheless, because of the inherent unpredictability of interest rates and other factors, actual results could differ materially from those projected in such forward-looking information.

We are exposed to market risk related to changes in interest rates with respect to borrowings under our unsecured revolving credit facility, commercial paper program and our unsecured term loans, certain of our mortgage loans that are floating rate obligations, mortgage loans receivable that bear interest at floating rates and available for sale securities. These market risks result primarily from changes in benchmark interest rates. To manage these risks, we continuously monitor our level of variable rate debt with respect to total debt and other factors, including our assessment of current and future economic conditions.

As of June 30, 2024 and December 31, 2023, the fair value of our secured and non-mortgage loans receivable, based on our estimates of current prevailing rates for comparable loans, was \$64.6 million and \$53.1 million, respectively.

The fair value of our fixed rate debt is based on current market interest rates at which we could obtain similar borrowings. Increases in market interest rates typically result in a decrease in the fair value of fixed rate debt while decreases in market interest rates typically result in an increase in the fair value of fixed rate debt. While changes in market interest rates affect the fair value of our fixed rate debt, these changes do not affect the interest expense associated with our fixed rate debt. Therefore, interest rate risk does not have a significant impact on our fixed rate debt obligations until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs.

To highlight the sensitivity of our fixed rate debt to changes in interest rates, the following summary shows the effects of a hypothetical instantaneous change of 100 basis points in interest rates (dollars in thousands):

	As of J	As of June 30, 2024		er 31, 2023
Gross book value	\$	12,535,864	\$	12,458,828
Fair value		12,030,929		11,994,321
Fair value reflecting change in interest rates:				
-100 basis points		12,509,527		12,457,648
+100 basis points		11,586,731		11,568,461

The table below sets forth certain information with respect to our debt, excluding premiums and discounts (dollars in thousands):

The date selow sels forth certain information with	•	of June 30, 2024		of December 31, 2023	,	of June 30, 2023
Balance:						
Fixed rate:						
Senior notes/Exchangeable senior notes	\$	9,386,263	\$	9,302,840	\$	9,305,076
Unsecured term loans		400,000		400,000		400,000
Mortgage loans and other		2,749,601		2,755,988		2,344,603
Subtotal fixed rate		12,535,864		12,458,828		12,049,679
Variable rate:						
Unsecured revolving credit facility		3,161		14,006		35,019
Unsecured term loans		300,000		677,501		477,758
Commercial paper notes		_		_		135,000
Mortgage loans and other		436,516		418,263		741,486
Subtotal variable rate		739,677		1,109,770		1,389,263
Total	\$	13,275,541	\$	13,568,598	\$	13,438,942
Percentage of total debt:						
Fixed rate:						
Senior notes/Exchangeable senior notes		70.7 %)	68.6 %)	69.2 %
Unsecured term loans		3.0		2.9		3.0
Mortgage loans and other		20.7		20.3		17.4
Variable rate:						
Unsecured revolving credit facility		_		0.1		0.3
Unsecured term loans		2.3		5.0		3.6
Commercial paper notes		_		_		1.0
Mortgage loans and other		3.3		3.1		5.5
Total		100.0 %)	100.0 %)	100.0 %
Weighted average interest rate at end of period:					-	
Fixed rate:						
Senior notes/Exchangeable senior notes		4.0 %)	3.8 %)	3.8 %
Unsecured term loans		4.7		4.7		4.7
Mortgage loans and other		4.3		4.2		3.9
Variable rate:						
Unsecured revolving credit facility		5.9		6.1		5.9
Unsecured term loans		6.3		6.3		6.1
Commercial paper notes		_		_		5.3
Mortgage loans and other		6.2		6.1		6.6
Total		4.2		4.1		4.1

The variable rate debt as of June 30, 2024 in the table above reflects, in part, the effect of \$142.3 million notional amount of interest rate swaps with maturities on March 2027, that effectively convert fixed rate debt to variable rate debt. In addition, the fixed rate debt as of June 30, 2024 in the table above reflects, in part, the effect of \$526.9 million and C\$643.8 million notional amount of interest rate swaps with maturities ranging from February 2025 to April 2031, in each case, that effectively convert variable rate debt to fixed rate debt.

The decrease in our outstanding variable rate debt at June 30, 2024 compared to December 31, 2023 is primarily attributable to the repayment of \$367.9 million (C\$500.0 million) unsecured term loan.

Our outstanding fixed rate debt at June 30, 2024 compared to December 31, 2023 was relatively consistent.

Assuming a 100 basis point increase in the weighted average interest rate related to our consolidated variable rate debt and assuming no change in our consolidated variable rate debt outstanding as of June 30, 2024 of \$739.7 million, interest expense on an annualized basis would increase by approximately \$7.4 million, or \$0.02 per diluted common share.

As of June 30, 2024 and December 31, 2023, our joint venture partners' aggregate share of total consolidated debt was \$302.2 million and \$297.5 million, respectively, with respect to certain properties we owned through consolidated joint ventures.

Total consolidated debt does not include our portion of unconsolidated debt related to investments in unconsolidated real estate entities, which portion was \$637.5 million and \$575.3 million as of June 30, 2024 and December 31, 2023, respectively.

As a result of our Canadian and United Kingdom operations, we are subject to fluctuations in certain foreign currency exchange rates that may, from time to time, affect our financial condition and operating performance. Based solely on our results for the six months ended June 30, 2024 (including the impact of existing hedging arrangements), if the value of the U.S. dollar relative to the British pound and Canadian dollar were to increase or decrease by one standard deviation compared to the average exchange rate during the year, our Normalized FFO per share for the six months ended June 30, 2024 would decrease or increase as applicable, by less than \$0.01 per share or less than 1%. We will continue to mitigate these risks through a layered approach to hedging looking out for the next year and continual assessment of our foreign operational capital structure. Nevertheless, we cannot assure you that any such fluctuations will not have an effect on our earnings.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of June 30, 2024, at the reasonable assurance level.

Internal Control Over Financial Reporting

There have been no changes in our internal controls over financial reporting during the second quarter of 2024 (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information contained in "Note 12 – Commitments And Contingencies" of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated by reference into this Item 1. Except as set forth therein, there have been no new material legal proceedings and no material developments in the legal proceedings reported in our 2023 Annual Report.

ITEM 1A. RISK FACTORS

In the second quarter of 2024, there were no significant new risk factors from those disclosed under Part I, Item 1A. "Risk Factors" of our 2023 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business, results of operations and financial condition.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

We do not have a publicly announced repurchase plan or program in effect. The table below summarizes repurchases of our common stock made during the quarter ended June 30, 2024:

	Number of Shares Repurchased ⁽¹⁾	Average Price Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs
April 1 through April 30	384	\$ 43.05		_
May 1 through May 31	412	43.81	_	_
June 1 through June 30	1,086	50.03		
Total	1,882	\$ 47.24		_

Repurchases represent shares withheld to pay taxes on the vesting of restricted stock and restricted stock units (including time-based and performance-based awards), or to pay taxes and/or exercise price on the exercise of stock options, granted to employees. The value of the shares withheld is the closing price of our common stock on the date the vesting or exercise occurred (or, if not a trading day, the immediately preceding trading day) or the fair market value of our common stock at the time of the exercise, as the case may be.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

Exhibit Number	Description of Document
4.1	Eighth Supplemental Indenture, dated May 13, 2024, among Ventas Realty, Limited Partnership, as Issuer, Ventas, Inc., as Guarantor, and U.S. Bank Trust Company, National Association (successor to U.S. Bank National Association), as Trustee (including the form of the 5.625% Senior Notes due 2034), incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K, filed on May 13, 2024.
10.1*	Fourth Amended and Restated Credit and Guaranty Agreement, dated as of April 24, 2024, among Ventas Realty, Limited Partnership, Ventas SSL Ontario II, Inc., Ventas Canada Finance Limited, Ventas UK Finance, Inc., and Ventas Euro Finance, LLC, as Borrowers, Ventas, Inc., as Guarantor, the Lenders identified therein, Bank of America, N.A., as Administrative Agent, and Bank of America, N.A., JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association, as L/C Issuers, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K, filed on April 24, 2024.
<u>22</u>	List of Guarantors and Issuers of Guaranteed Securities.
31.1	Certification of Debra A. Cafaro, Chairman and Chief Executive Officer, pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.
<u>31.2</u>	Certification of Robert F. Probst, Executive Vice President and Chief Financial Officer, pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.
<u>32.1</u> +	Certification of Debra A. Cafaro, Chairman and Chief Executive Officer, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. § 1350.
<u>32.2</u> +	Certification of Robert F. Probst, Executive Vice President and Chief Financial Officer, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. § 1350.
101	The following materials from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, formatted in XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Equity, (v) the Consolidated Statements of Cash Flows and (vi) Notes to the Consolidated Financial Statements.
104	Cover Page Interactive Data File (formatted as inline XBRL).

^{*} In accordance with Item 601(a)(5) of Regulation S-K certain schedules and exhibits have not been filed. The Company hereby agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.

⁺ This exhibit will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 2, 2024

VENTAS, INC.	
By:	/s/ DEBRA A. CAFARO
	Debra A. Cafaro Chairman and Chief Executive Officer
By:	/s/ ROBERT F. PROBST
	Robert F. Probst
	Executive Vice President and
	Chief Financial Officer

<u>List of Guarantors and Issuers of Guaranteed Securities</u>

As of June 30, 2024, Ventas, Inc. is the guaranter of the outstanding guaranteed debt securities of its subsidiaries, as listed below.

Debt Instrument	Issuer
4.125% Senior Notes due 2024 Series B (CAD)	Ventas Canada Finance Limited
2.65% Senior Notes due 2025	Ventas Realty, Limited Partnership
3.50% Senior Notes due 2025	Ventas Realty, Limited Partnership
4.125% Senior Notes due 2026	
	Ventas Realty, Limited Partnership
3.75% Exchangeable Senior Notes due 2026	Ventas Realty, Limited Partnership
3.25% Senior Notes due 2026	Ventas Realty, Limited Partnership
3.85% Senior Notes due 2027	Ventas Realty, Limited Partnership
2.45% Senior Notes due 2027 Series G (CAD)	Ventas Canada Finance Limited
4.00% Senior Notes due 2028	Ventas Realty, Limited Partnership
5.398% Senior Notes due 2028 Series I (CAD)	Ventas Canada Finance Limited
4.40% Senior Notes due 2029	Ventas Realty, Limited Partnership
5.10% Senior Notes due 2029 Series J (CAD)	Ventas Canada Finance Limited
3.00% Senior Note due 2030	Ventas Realty, Limited Partnership
4.75% Senior Note due 2030	Ventas Realty, Limited Partnership
3.30% Senior Notes due 2031 Series H (CAD)	Ventas Canada Finance Limited
2.50% Senior Note due 2031	Ventas Realty, Limited Partnership
5.625% Senior Note due 2034	Ventas Realty, Limited Partnership
6.90% Senior Notes due 2037	Ventas Realty, Limited Partnership
6.59% Senior Notes due 2038	Ventas Realty, Limited Partnership
5.70% Senior Notes due 2043	Ventas Realty, Limited Partnership
4.375% Senior Notes due 2045	Ventas Realty, Limited Partnership
4.875% Senior Notes due 2049	Ventas Realty, Limited Partnership

- I, Debra A. Cafaro, certify that:
- 1. I have reviewed this Quarterly Report on Form 10-Q of Ventas, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report, any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 2, 2024

/s/ DEBRA A. CAFARO

Debra A. Cafaro Chairman and Chief Executive Officer

- I, Robert F. Probst, certify that:
- 1. I have reviewed this Quarterly Report on Form 10-Q of Ventas, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report, any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 2, 2024

/s/ ROBERT F. PROBST

Robert F. Probst

Executive Vice President and Chief Financial Officer

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Ventas, Inc. (the "Company") for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Debra A. Cafaro, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 2, 2024

/s/ DEBRA A. CAFARO

Debra A. Cafaro

Chairman and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Ventas, Inc. (the "Company") for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert F. Probst, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 2, 2024

/s/ ROBERT F. PROBST

Robert F. Probst

Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.